Diagnostic and prognostic markers in sepsis by Gille-Johnson, Patrik
 From THE DEPARTMENT OF MEDICINE,  
DIVISION OF INFECTIOUS DISEASES 
Karolinska Institutet, Stockholm, Sweden 
 
DIAGNOSTIC AND 
PROGNOSTIC MARKERS 
IN SEPSIS 
Patrik Gille-Johnson 
 
 
Stockholm 2013 
 
 
 
  
 
 All previously published papers were reproduced with permission from the 
publisher. 
 
Published by Karolinska Institutet. Printed by Larserics. 
 
© Patrik Gille-Johnson, 2013 
ISBN 978-91-7549-288-9 
 
 “If a man does not keep pace with his companions, 
perhaps it is because he hears a different drummer. 
Let him step to the music which he hears, 
however measured or far away.” 
-Henry David Thoreau 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
               Stockholm 2013 
 
 
 
 Institutionen för medicin, Huddinge 
Diagnostic and prognostic markers in 
sepsis 
AKADEMISK AVHANDLING 
som för avläggande av medicine doktorsexamen vid  
Karolinska Institutet offentligen försvaras i Welandersalen,  
ingång B2, plan 00, Karolinska Universitetssjukhuset, Solna 
Fredagen den 22 november 2013, kl. 09:00 
av 
Patrik Gille-Johnson 
 
Huvudhandledare:  
Professor Jan Andersson 
Karolinska Institutet 
Institutionen för medicin, Huddinge 
 
Bihandledare:  
Docent Bengt Gårdlund 
Karolinska Institutet 
Institutionen för medicin, Huddinge 
 
 
Fakultetsopponent: 
Docent Per Åkesson 
Lunds Universitet 
Institutionen för medicinska vetenskaper 
 
Betygsnämnd: 
Docent Anders Oldner 
Karolinska Institutet 
Institutionen för fysiologi och farmakologi 
 
Professor Anna Norrby-Teglund  
Karolinska Institutet 
Institutionen för medicin, Huddinge 
 
Docent Karlis Pauksens 
Uppsala Universitet 
Institutionen för medicinska vetenskaper 
 
  
 ABSTRACT 
Sepsis is a life-threatening disease affecting millions of people globally. The more 
severe forms are considered to be a consequence of an unbalanced systemic 
inflammatory response to infection, causing organ dysfunction, vascular leakage and 
hypotension. An early diagnosis followed by appropriate antimicrobial therapy is 
critical for the outcome. Conversely, inappropriate antibiotic use will escalate 
antibiotic resistance. Therapeutic guidance from microbiological cultures is lacking 
in the early hospital course, and better tools are needed for prompt identification and 
severity stratification of sepsis patients.  
 
The aim of this thesis was to assess the clinical impact of severe sepsis and the 
diagnostic properties of clinical and biological markers in patients with a suspected 
or established serious infection.  
 
The diagnostic value of clinical and laboratory variables in predicting infections that 
require antibiotic treatment was evaluated in a prospective observational study of 
adult patients with suspected severe infections. We also analyzed the relations 
between severe sepsis, systemic inflammatory response syndrome (SIRS), and the 
clinical course. 
We concluded that increased C-reactive protein, white blood cell count, respiratory 
rate and a decreased hemoglobin level contributed independently to an accurate 
selection of patients for antibiotic therapy. Procalcitonin did not provide guidance on 
antibiotic decisions, but was associated with bacteremia and severe sepsis. In 
addition, severe sepsis was a common condition (42%), but mortality was low (5%), 
suggesting that severe sepsis is a more benign condition than earlier reported. SIRS 
did not exhibit discriminative ability in the classification of sepsis. 
 
We used the enzyme-linked immunospot (ELISpot) assay to study the spontaneous 
as well as the lipopolysaccharide (LPS)-induced secretion of a number of pro- and 
anti-inflammatory cytokines from leukocytes of septic patients and healthy controls. 
We concluded that circulating leukocytes did not appear to be the source of the 
increased plasma levels of cytokines observed in sepsis. A selective sepsis-induced 
downregulation of cytokine secretion in response to LPS was found: while the 
numbers of IL-6 and TNF-  secreting cells remained similar, significantly fewer IL-
1 , IL-10, IL-12p40 and GM-CSF secreting cells were seen in samples from septic 
patients as compared to healthy controls. The reduced number of cytokine secreting 
cells in response to LPS stimulation correlated with disease severity. 
 
LPS-induced cytokine secretion from polymorphonuclear cells (PMN) and 
peripheral blood mononuclear cells (PBMC) from healthy donors was analyzed by 
ELISpot. PMN were found to secrete the two chemokines IL-8 and MIP-1β in 
response to LPS. Also TNF was secreted but by significantly fewer cells. PBMC had 
a broader cytokine secreting repertoire and released considerably larger amounts of 
the investigated cytokines, with CD14+ monocytes being the primary source of 
production. 
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1 BACKGROUND 
 
1.1 THE PROBLEM 
 
1.1.1 A persistently deadly disease 
Case 1, ancient Greece: 
 “Criton, in Thasus, while still on foot, and going about, was seized with a violent 
pain in the great toe; he took to bed the same day, had rigors and nausea, recovered 
his heat slightly, at night was delirious. On the second day, swelling of the whole 
foot, and about the ankle erythema, with distension, and small bullae; acute fever; he 
became furiously deranged; alvine discharges bilious, unmixed, and rather frequent. 
He died on the second day from the commencement.” [1] 
 
Case 2, Stockholm, Sweden, 21
st
 century: 
A previously healthy male, age 61, presented to the emergency department at the 
hospital with an infected wound acquired when bathing. He was given antibiotic 
treatment against ”erysipelas”. While at work 2 days later onset of nausea, blurred 
vision, rigors and a swollen, aching lower leg. Physical/laboratory examination: 
Hypotension, altered mental status, coagulation abnormalities. Thickened and 
discoloured lower limb with blisters. Progression to multiple organ failure. 
Interventions: broad antibiotic therapy; repeated surgery; hyperbaric oxygen 
treatment; intensive organ support, including renal replacement therapy. On the third 
day of hospital stay, he died. 
 
Although some 2400 years of accumulated medical knowledge separate these two 
cases of sepsis, they exhibit striking similarities in that they share not only the clinical 
picture, but also the fatal outcome. They illustrate the fact that modern day clinicians, 
despite clinical skills and tools immeasurably superior to those available to Hippocrates 
and his peers, still have to tolerate being reduced to helpless bystanders when a 
microbial assault strikes with full force.  
 
1.1.2 The magnitude 
The true impact of sepsis on modern society is not known. There are no population-
based prospective cohort studies, and most estimates are based on studies of hospital 
discharge data. A diversity of defining criteria has been used in these investigations, 
resulting in substantial variability in calculations of incidence and mortality between 
studies [2].  One frequently cited U.S. study found the incidence of severe sepsis to be 
300 per 100,000 people, of which half required intensive care and 28.6 % died [3]. The 
incidence and total mortality seem to be increasing [2, 4-6], likely reflecting ageing and 
more vulnerable populations. Crude estimates of fatality rates vary between 20-50% for 
severe sepsis and 40-80% for septic shock. Recently there has been an encouraging 
trend toward decreasing case fatality rates, possibly due to earlier recognition and 
treatment [2, 7]. However measured, sepsis remains a major health problem, affecting 
millions of people globally, and with persistently high mortality rates [3, 8-10].  
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The most common cause is pneumonia, accounting for slightly less than half of the 
cases, followed by abdominal and urinary tract infections [8, 11, 12]. 
Blood cultures are generally positive in about a third of cases, and another third 
remain of indeterminate microbiological origin [8, 12, 13]. The most commonly found 
causative organisms are E. coli, Staphylococcus aureus and pneumococci [12-14]. 
 
1.2 THE WORD 
The word “sepsis” (σηψις) is of Greek origin and refers to the decomposition of 
organic matter. It was used by Hippocrates to describe harmful, putrid infection [15, 
16]. After antiquity, the term was used occasionally until the mid 19
th
 century. During 
this period great progress within the fields of anatomy and pathology had been made, 
which, together with the recent introduction of anaesthesia in 1846, paved the way for a 
wider use of surgery. Operative procedures were, however, heavily burdened by severe 
infectious complications, often with fatal results [17, 18]. “Sepsis”, together with the 
synonymous “septicaemia”, was now increasingly used to describe the general 
infection, “blood poisoning”, which often accompanied an inflamed wound. The terms 
became established and were introduced into medical textbooks and dictionaries [19, 
20]. 
  
1.3 THE DISEASE 
1.3.1 Clinical picture, diagnosis and definitions 
Although the signs and symptoms of sepsis may be highly variable, it takes only 
little experience of acute care in order to recognize the usual clinical picture, 
characterized by fever, chills, general malaise and signs of physiological strain. Still, 
defining specific and useful diagnostic criteria for sepsis has remained a complicated 
issue ever since the modern usage of the term was introduced. The predicament is 
exemplified in a text from that epoch: “During the years 1870 to 1872 alone, more than 
forty original researches on sepsis...were published...And yet at the present time... it is 
not even possible to give a general definition of the term..., which could correctly 
represent all the different conceptions of its nature” [21]. The frustration contained in 
these words was to be inherited by successive generations of the medical community, 
despite an enhanced knowledge of underlying pathophysiological mechanisms. The 
lack of uniform definitions led to great disparities between study populations, and 
sepsis trials were marred by poor generalizability [22]. In an attempt to resolve this 
problem, a consensus conference of the American College of Chest Physicians (ACCP) 
and the Society of Critical Care Medicine (SCCM) introduced new diagnostic 
definitions in the early 1990s, with the intention to provide criteria that were apt for 
both clinical practice and standardization of research protocols [23]. Central to the 
proposed definitions was the presence of a “systemic inflammatory response 
syndrome” (SIRS), a physiologic reaction commonly seen in intensive care patients in 
response to conditions like trauma, burns and infection. SIRS was defined by at least 
two of the following signs: an abnormal body temperature, tachycardia, tachypnea or 
an abnormal white blood cell count (WBC) (Box 1). Sepsis was defined as SIRS 
caused by an infection (Fig. 1). It was also suggested that SIRS could progress into a 
more severe state of organ failure, coined “multiple organ dysfunction syndrome” 
(MODS). 
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Two or more of the following: 
Temperature >38°C or <36°C 
Heart rate >90/min 
Respiratory rate >20/min or PaCO2 <4,3 kPa 
White blood cell count >12x109/l or <4x109/l, or >10% immature forms 
 
To avoid confusion, the terms “septicaemia” and “septic syndrome” were abolished, 
while “severe sepsis” was defined as sepsis associated with organ dysfunction, 
hypoperfusion, or hypotension. Finally, the term “septic shock” was reserved for cases 
of severe sepsis with hypotension refractory to fluid replacement. “Sepsis”, “severe 
sepsis” and “septic shock” now defined three progressive disease stages of increasing 
severity (Fig. 2). 
 
 
 
 
 
 
 
 
 
 
1.3.1.1 Dear SIRS, were you aware of what you did? 
The novel definitions facilitated comparisons between studies, and consequently 
became a standard for the enrolment of patients in sepsis trials [24]. Criticism was, 
BOX 1. SIRS-defining criteria. Data adapted from Bone et al. [23] 
FIGURE 1. Interrelationship between infection, systemic inflammatory response syndrome 
(SIRS), sepsis, and associated conditions. Adapted from Bone et al. [23] 
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nevertheless, soon to follow. SIRS criteria were considered overly inclusive as they 
were readily met by large numbers of patients across the spectrum of acute care, 
regardless of disease severity [25, 26]. On the other hand, the definition could also be 
too restrictive when otherwise overtly septic patients did not satisfy the criteria, and 
were prevented from study enrolment [27, 28]. As a result, the original ACCP/SCCM 
criteria were revisited by a second consensus conference in 2001 [29]. The concepts of 
sepsis, severe sepsis, and septic shock were acknowledged, but in order to facilitate a 
bedside diagnosis of sepsis, the original SIRS criteria were expanded into a 
smorgasbord of parameters, ready to pick from by the clinician (Box 2). Although these 
criteria provided a more complete description of sepsis as a clinical entity, it also made 
the diagnosis more diffuse and subject to interpretation. The fact that hypoperfusion, 
hypotension and organ dysfunction parameters, which define severe sepsis, were now 
introduced among the sepsis (only) defining parameters, only aggravated this situation. 
Hence, researchers continue to use the original 1991 sepsis criteria and SIRS definition 
(Box 1) for the enrolment of patients in sepsis trials [12, 30-32]. 
 
 
 
1.3.2 Current understanding of sepsis pathogenesis 
The last decades have seen extraordinary advances in the understanding of the 
molecular mechanisms that regulate the host response to infection. The following 
paragraphs attempt to briefly summarize some of the key findings in relation to sepsis. 
  
1.3.2.1 Proinflammatory mechanisms 
1.3.2.1.1 Pattern-recognition receptor activation 
When pathogens invade otherwise sterile tissues, immune cells initiate a host 
defense response triggered by the recognition of conserved pathogen associated 
molecular patterns (PAMPs) through a number of receptors known as pattern-
recognition receptors (PRRs).  Moreover, PRRs can react to tissue damage through the 
recognition of endogenous mediators released from dying cells. These mediators are 
commonly referred to as danger associated molecular patterns (DAMPs), and may 
explain the SIRS elicited by non-infectious injury like trauma or burns. In sepsis both 
PAMPs and DAMPs contribute to the inflammatory process. 
FIGURE 2. The progressive severity stages of sepsis. Increasing severity is characterized 
by lower incidence and increased case fatality rates. 
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Toll-like receptors (TLRs), a group of transmembrane proteins, belong to the PRR 
family and are central to the initiation of a cellular immune response.  This intricate 
process can be exemplified by the TLR4 recognition of bacterial lipopolysaccharide 
(LPS, also known as endotoxin), a most potent PAMP: Circulating LPS-binding protein 
(LBP) forms a complex with LPS, which binds to the receptor CD14 on 
monocytes/macrophages. TLR4 binds to the LBP-LPS-CD14 complex via an auxiliary 
protein, MD2, and subsequently activates an intracellular signal-transduction pathway 
that releases transcription factors like nuclear factor κB (NF-κB). Activated NF-κB 
Sepsis: documented or suspected infection and some of the following: 
General parameters 
 Fever (core temperature >38.3°C) 
 Hypothermia (core temperature <36°C) 
 Heart rate >90 bpm or >2 SD above the normal value for age 
 Tachypnea 
 Altered mental status 
 Significant edema or positive fluid balance (>20 ml/kg over 24 h) 
 Hyperglycemia (plasma glucose >120 mg/dl or 7.7 mmol/l) in the absence of 
diabetes 
Inflammatory parameters 
 Leukocytosis (white blood cell count >12x109/l) 
 Leukopenia (white blood cell count <4x109/l) 
 Normal white blood cell count with >10% immature forms 
 Plasma C reactive protein>2 SD above the normal value 
 Plasma procalcitonin >2 SD above the normal value 
Hemodynamic parameters 
 Arterial hypotension (systolic blood pressure <90 mmHg, mean arterial pressure <70, 
or a systolic blood pressure decrease >40 mmHg in adults or <2 SD below normal 
for age) 
 Mixed venous oxygen saturation >70% 
 Cardiac index >3.5 l/min/m2 
 Organ dysfunction parameters 
 Arterial hypoxemia (PaO2/FIO2 <300 mmHg or <40 kPa) 
 Acute oliguria (urine output <0.5 ml/kg/h for at least 2 h) 
 Creatinine increase ≥0.5 mg/dl or ≥45 µmol/l 
 Coagulation abnormalities (international normalized ratio >1.5 or activated partial 
thromboplastin time >60 s) 
 Ileus (absent bowel sounds) 
 Thrombocytopenia (platelet count <100,000/µl) 
 Hyperbilirubinemia (plasma total bilirubin >4 mg/dl or 70 mmol/l) 
Tissue perfusion parameters 
 Hyperlactatemia (>3 mmol/l) 
 Decreased capillary refill or mottling 
Severe sepsis: sepsis with organ dysfunction, hypoperfusion or hypotension 
Septic shock: severe sepsis with hypotension refractory to intravenous fluid replacement 
 
BOX 2. 2001 international sepsis definitions. Data adapted from Levy et al.[29] 
 
 6 
moves from the cytoplasm to the nucleus and induces transcription of genes coding for 
a multitude of proinflammatory proteins, e.g. the cytokines tumor necrosis factor 
(TNF), interleukin-1 (IL-1) and IL-6. TNF and IL-1 are early and potent initiators of 
the inflammatory response cascade, sharing an individual capacity to inflict sepsis-like 
organ failure and circulatory collapse when given in high doses. In contrast, IL-6 does 
not cause tissue damage or shock, but is a principal inducer of fever and the acute phase 
response. This involves a shift in the production of hepatic plasma proteins toward a 
profile more adapted to host defence, with increased release of numerous proteins, 
including complement factors, LBP and C-reactive protein (CRP), which is also a 
clinically important inflammatory marker [33-36]. 
The resulting acute inflammation has potent effects on the local microcirculation, 
characterized by vasodilation, increased vascular permeability, and passage of 
leukocytes and circulating immune mediators into the site of infection.   
 
1.3.2.1.2 Leukocytes 
Leukocytes, blood cells of the immune system, can roughly be divided into 
polymorphonuclear cells (PMN), also called granulocytes, and mononuclear cells 
(PBMC).  
Neutrophils are PMN that form the majority of the blood's leukocytes. They play a 
key role in the frontline host defense to bacterial infection, and an accumulation of 
neutrophil granulocytes is considered the hallmark of acute inflammation. The 
cytoplasm is filled with granules containing numerous anti-microbial substances, which 
will be released (degranulate) in response to inflammatory signals. Neutrophils are 
rapidly recruited to injured or infected tissues, attracted by inflammatory mediators like 
TNF, IL-1, IL-8 and nitric oxide (NO), expressed by activated tissue macrophages and 
endothelium. They roll along and adhere to the vessel wall, before they transmigrate 
into the tissue where they phagocytose, damage and kill microorganisms. Granule 
content is released into tissues in order to kill extracellular microorganisms, but can 
also cause collateral tissue damage. Neutrophils secrete only moderate amounts of 
cytokines, predominantly with a chemotactic profile, e.g. IL-8, which is central for the 
recruitment of additional neutrophils. After phagocytosis, they undergo apoptosis and 
are cleared from the inflammatory site by macrophages in an anti-inflammatory manner 
[33, 37]. 
Monocytes are mononuclear cells that constitute 5-10% of circulating leukocytes. 
Most monocytes are predestined to migrate into tissues where they mature into resident 
macrophages, specialized to protect their microenvironment and to repair tissue. Like 
neutrophils, monocytes/macrophages kill microbes through phagocytosis, but they also 
orchestrate the immune response via a plethora of mediators. This includes 
prostaglandins, leukotriens, platelet activating factor (PAF) and a wide array of 
cytokines. In addition, monocytes/macrophages are also antigen-presenting cells 
(APCs), carrying human leukocyte antigen (HLA) receptors with the capability to 
ligate and display foreign antigens to antigen-specific T-lymphocytes, thus constituting 
an important link between the innate and specific immune defense [33, 38].  
Lymphocytes make up the larger part of PBMC and represent the specific immune 
defense. They circulate between the blood and lymphoid organs and are activated by 
specific microbial antigens presented by APC. Lymphocytes attack the antigen, either 
by antibodies produced by B-lymphocytes, cytotoxic granules from cytotoxic 
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T-lymphocytes, or by the recruitment of macrophages and other immune cells by helper 
T-lymphocytes. A fully activated specific immune response requires considerably more 
time than the immediate innate response, often weeks [33]. 
 
1.3.2.1.3 The coagulation system and the endothelium 
The coagulation system is triggered by expression of tissue factor on IL-6 activated 
endothelium and monocytes, resulting in thrombin generation and enhanced platelet 
adhesion and aggregation. Together with impaired anticoagulant mechanisms, a 
procoagulant state with local fibrin deposition is elicited, contributing to the 
containment of the infection, but also tissue hypoperfusion.  
While an increased endothelial permeability is a prerequisite for the extravasation of 
neutrophils and plasma into the site of infection, an exuberant inflammatory response 
may lead to apoptosis and detachment of endothelial cells, with an ensuing loss of 
barrier function [33, 39, 40]. 
 
1.3.2.1.4 The complement system 
In parallel with phagocytosis, the complement system forms the principal 
antibacterial system of the immune defense. Subsequent to immune activation, this 
system of more than 30 plasma proteins and receptors contributes to the elimination of 
microbes by two key mechanisms: opsonization and cell lysis. Opsonization facilitates 
phagocytosis by the adhesion of complement proteins to the bacterial cell surface, 
while cell lysis is caused by a membrane attack complex consisting of complement 
factors C5-9. This process is initiated by the cleavage of C5 into C5a and C5b. 
Together with C6-9, C5b form the membrane attack complex, while C5a has 
anaphylatoxin activity, increases vascular permeability and recruits inflammatory cells 
to the site of infection. Elevated levels of several complement factors have been 
associated with sepsis, and a number of studies have pointed to C5a as a significant 
inducer of hemodynamic and coagulatory perturbation [33, 35, 41].  
 
1.3.2.1.5 The peril 
Although essential to the immune response, it is believed that high levels of PAMPs 
from invading microorganisms can, in concert with DAMPs from damaged host tissue, 
lead to an overstimulation of immune cells which leads to the uncontrolled systemic 
response seen in fulminant cases of sepsis. The exact mechanisms by which sepsis 
causes multiple organ failure remain unclear, but the general conception is that macro- 
and microvascular effects due to widespread hyperinflammation and coagulation 
compromise tissue perfusion and oxygen delivery. Vasodilation, increased vascular 
permeability and depressed myocardial function lead to a pathophysiologic phenotype 
distinguished by hypovolemia and hypotension, while a hypercoagulant state results in 
microvascular thrombosis, in its most extreme form termed disseminated intravascular 
coagulation (DIC). Sepsis has also been demonstrated to impair mitochondrial function, 
possibly contributing to organ dysfunction [34, 42]. 
 
1.3.2.2 Anti-inflammatory mechanisms and immunosuppression 
In the cross-talk between the systems of pattern-recognition, complement and 
coagulation there is an abundance of counter-regulatory mediators aiming to modulate 
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an excessive proinflammatory response. Among these are anti-inflammatory cytokines 
like IL-10, IL-1 receptor antagonist (IL-1ra), and transforming growth factor β (TGF- 
β). IL-6, in contrast to its proinflammatory properties, also exhibits anti-inflammatory 
effects, illustrating the complexity of cytokine interactions. IL-6 inhibits the production 
of IL-1 and TNF and stimulates the release of IL-10 and cortisol [33]. Circulating 
immune cells develop diminished antigen presenting capacity and responsiveness to 
secondary inflammatory stimulation, which in combination with negative regulators of 
TLR signaling and inducers of immune cell apoptosis contribute to an anti-
inflammatory pattern. In addition, there is a neuro-endocrine-immune network in which 
the cholinergic nervous system responds to efferent signals by the release of 
acetylcholine, which inhibits proinflammatory cytokine release through ligation to 
acetylcholine receptors on macrophages (Fig. 3) [35, 36].  
There is mounting evidence that critically ill patients who survive the initial phase of 
sepsis are subjected to a more immunosuppressive condition, with a propensity to 
develop secondary opportunistic infection and reactivation of latent viral infection [43, 
44].  
 
1.3.3 The aggressors 
When reviewing the literature on sepsis definitions, it is striking how little interest 
that is devoted to the very roots of the disease - the microorganisms. A basic 
understanding of the microbial perspective is, however, fundamental to the 
understanding of sepsis. 
With some simplification allowed, it can be argued that while the earlier part of the 
medical development of the 19
th
 century was dominated by advances in cellular 
pathology, the latter part saw the dawn of another scientific revolution; bacteriology, 
and the establishment of the germ theory.  
Although bacteria were first observed in 1675 by the Dutch microscope constructor 
Leeuwenhoek [17], their causative role in disease was not elucidated until the 
pioneering achievements by scientists like Koch and Pasteur, along with a number of 
their contemporaries [18]. While the pathogenic role of bacteria is an integrated part of 
today’s common knowledge, the debate was animated within the scientific community 
at the time of their discoveries, in concordance with the structure of events that 
eventually lead to a paradigm shift [45].  
One of the more prominent scientists who did not accept the germ theory was 
Rudolf Virchow, the father of cellular pathology [17]. As he was himself a scientific 
revolutionary, it would probably be unwise to discard his doubts as a mere act of ill-
founded conservatism. In fact, a sceptic´s case could easily be constructed: First, the 
same bacteria could be found in tissues, e.g. wounds, whether there were signs of 
disease or not. Second, the septic reaction induced by injection of bacteria into animals 
could be reproduced by the injection of various chemical substances [21]. Third, while 
bacteria could easily be cultured from the blood of animals during experimental 
septicaemia, this was not the case in man, where it was “evident, from the large 
percentage of negative results even in the severest type of disease, that the search for 
the specific causes of disease by this method will often prove futile” [21, 46]. So which 
was the actual pathogenic role of bacteria? These were issues that had to be dealt with 
by the scientists of the new era. They were duly resolved, chiefly by studies of host 
defense mechanisms, which will be discussed in a subsequent section. 
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Sepsis is commonly associated with bacterial infections, yet all known types of 
microorganisms can cause infections evolving to sepsis, exemplified by malaria 
(caused by a protozoan), influenza (a viral infection), and candidemia (a fungal 
invasion of the bloodstream). Although fungal sepsis has become increasingly common 
FIGURE 3. The interaction between pathogens and the host is mediated initially via an 
interaction between pathogen-associated molecular patterns (PAMPs) and Toll-like 
receptors (TLRs). This interaction can result in the release of danger-associated molecular 
patterns (DAMPs), which have the ability to further amplify the inflammatory response, at 
least in part, via TLRs. The initial inflammation activates afferent signals that are relayed to 
the brain; subsequent activation of vagus efferent activity inhibits cytokine synthesis via 
pathways dependent on acetylcholine receptors on macrophages and other cells through 
the cholinergic anti-inflammatory pathway (the inflammatory reflex). The resulting innate 
response of immune cells can result in a balanced reaction leading to pathogen elimination 
and tissue recovery, or an unbalanced reaction that on the one hand can lead to 
exaggerated inflammation and tissue injury, and on the other hand to immune suppression 
(reprinted from van der Poll et al. [35] with permission from Elsevier). 
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in the last decades [7], sepsis remains a predominantly bacterial disease [8, 13].  
To the bacteria, a human host represents a nutritious environment offering 
colonization and prospering. This is a highly competitive milieu, in which only 
mechanisms that promote bacterial persistence and spread will be favoured by natural 
selection. The distinction between human health and disease is simply not relevant in 
this context; it is rather the result of mechanisms and sites chosen by the microorganism 
for proliferation. In general, the competition for a favourable niche within the host is to 
the advantage of microbes that contribute to the host´s well-being (mutualists) or those 
that do not cause harm (commensals). Hence, commensalism and mutualism are the 
principal forms of human-microbe relations, established early in the life of the 
individual and essential to human biology [47].  
A pathogen, on the other hand, faces impressive challenges. By causing harm to the 
host, it will activate a response that endangers its own existence. In order to become 
successful under such dire circumstances, pathogens use a wide array of 
counterstrategies. These include antiphagocytic capsules, toxins that destroy immune 
cells and anatomic barriers, and various refined biochemical interactions to evade or 
manipulate host defence mechanisms [35, 41, 48].   
A number of bacterial species regularly cause sepsis in individuals with an 
apparently intact immune system, e.g. Staphylococcus aureus, Streptococcus 
pneumoniae, β-hemolytic streptococci, Neisseria meningitidis and various 
enterobacteriacae. They are principal human pathogens that exhibit a high degree of 
virulence. From an evolutionary point of view, causing serious disease that threatens 
host viability can, literally, be a “dead end” to the microbe, unless transmission to a 
new host is secured in advance. The higher the virulence, the greater the need will be 
for efficient transmission [47]. The principal pathogenic species have solved this by a 
sufficiently high transmissibility, but their evolutional success likely depends more on 
their ability to remain peaceful most of the time. Although feared as pathogens, their 
main role is that of commensal members of the indigenous microbiota, causing no or 
only mild symptoms of infection. The occasional cases of sepsis caused by these 
organisms are exceptions to the rule, representing only a minuscule part of their 
interaction with humans. What distinguishes them from other commensals is their 
inherent capacity to breach barriers and invade highly protected anatomic sites of vital 
importance to the host, and to persist and multiply in these environments through 
adaptive mechanisms. 
There are, in addition, a number of commensal species that may act as pathogens 
solely when the delicate balance between host defense and microbiota is disrupted. In 
the presence of disease or medication that affects the host´s defense system or 
microbial ecology, opportunities arise for these microbes to step forward and thrive 
outside their ordinary confines, thereby causing disease. They are opportunists, of 
which Pseudomonas aeruginosa and Candida albicans are common examples.  
There is, however, no sharp demarcation between principal pathogens and 
opportunists when it comes to sepsis, where a more or less opportunistic behaviour can 
be expected from all pathogens, exemplified by the higher incidence seen in individuals 
of advanced age and/or with debilitating co-morbid conditions, regardless of causative 
pathogen [3, 8, 49].  
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1.4 THEORIES AND THERAPIES 
The construction of modern sepsis theory is intimately associated with two parallel 
developments in medicine: First, the emergence and evolution of immunology, which 
renders the clinical picture interpretable through molecular mechanisms. Second, the 
establishment of intensive care treatment with the capability of lifesaving organ 
support, which would carry the patients through previously irreversible stages of 
disease and provide opportunities for novel therapies.  
In the following, a brief outline of some significant steps in this evolution will be 
given. 
 
1.4.1 The response 
 
 
 
 
 
1.4.1.1 We are not defenseless 
As previously mentioned, the fact that blood cultures were often negative even in 
severely septic patients was vexing to the scientists of the late 1800s. In a review “On 
the present state of knowledge in bacterial science” of 1886, the author concludes that 
“the number of micro-organisms present in septicaemic blood of man is so small that it 
is frequently impossible to obtain pure cultures” and “It therefore seems natural to 
suppose that the micro-organisms of septicaemia are capable of producing some 
poisonous substance which kills the patient” [21]. Within the next few years, this 
hypothesis was corroborated by the discoveries of diphtheria and tetanus toxins by 
Roux and Yersin, scientists at the brand new Pasteur institute [18]. Diphtheria and 
tetanus, while terrifying and lethal diseases at the time, could not readily be termed 
“septic”, as their symptoms were of a different nature. Still, toxin-mediated injury later 
proved to be of major importance in the pathogenesis of sepsis, although not imperative 
for the causation [35].  
The toxin discovery also became the starting point for a chain of scientific endeavors 
that eventually led to the establishment of a new academic discipline, sprung out of 
bacteriology. In 1890, Behring and co-workers could demonstrate antitoxins, 
substances produced in the blood of animals injected with diphtheria and tetanus 
bacteria, which would neutralize the toxins and cure the disease when given to 
symptomatic animals [18, 50].  
Another German, Paul Ehrlich, made a major theoretical breakthrough when 
developing the serum therapy introduced by Behring. In 1897, he conceived the idea of 
multiple specific receptors on host cells that would multiply abundantly when triggered 
by harmful foreign substances, in order to neutralize them. He termed these specific 
receptors “antibodies”, and the notion of a specific, humoral immune response was 
born [18, 51, 52].  
A couple of decades earlier, Ilya Mechnikov, a young professor of zoology at the 
University of Odessa, had been tormented by a depression with suicidal ideation. To 
spare his family from embarrassment, he decided to perish with style - through a 
scientific experiment. He inoculated himself with relapsing fever to find out whether it 
“Except on few occasions, the patient appears to die from 
the body’s response to infection rather than from it.” 
-William Osler 
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was transmissible by the blood. It was, and he became severely ill, but the suicide 
attempt failed. Mechnikov was cured from both the fever and the depression and went 
on to study migratory cells challenged with foreign material. Building on his 
observations, he formulated the theory of phagocytosis, claiming that cells take a 
central part in the host defense through the active engulfment of microbial invaders, as 
distinct from passively being invaded, which was the dominating view [51, 52]. 
Mechnikov had thereby brought the concept of an unspecific, cellular immune defense 
into existence. He subsequently studied the function of phagocytes in various infections 
and, in a paper on streptococcal sepsis, distinguished between phagocytes and 
introduced the term “macrophage” to describe the larger of the cells [53] (the smaller 
“microphages” were neutrophil leukocytes).  
The findings by Ehrlich and Mechnikov were, at the time, too discordant to be 
unified into a general theory of host defense, and instead a “humoral” and a “cellular” 
school was formed, leading to heated scientific disputes [52, 54]. Their theories, 
however, shared a common theme: when pathogens attack, the human host is not a 
defenseless victim – rather, we are capable of forceful countermeasures. Immunology 
was born, and Ehrlich and Mechnikov were jointly awarded the Nobel Prize of 1908 in 
recognition of their work. 
Subsequent research found their theories to be complimentary; the cooperation 
between phagocytes and antibodies is fundamental to an efficacious elimination of 
microbes. (Further studies have added to the knowledge of how intricately entangled 
the mechanisms of the innate, unspecific “cellular” defense and the acquired specific 
“humoral" defense are. Still, the division of the immune system along these lines has 
shown to be remarkably robust over time. Whether this theoretical separation actually 
contributes to our understanding of the immune defense, as we know it today, could be 
the matter of a scientific debate. This will, however, have to take place elsewhere, as it 
would be beyond the scope of this thesis.) 
 
1.4.1.2 The body at war: collateral damage 
To a great extent, the landscape of current sepsis theory owes its features to the 
studies of one single molecule and its effects: endotoxin.   
Richard Pfeiffer, a co-worker of Koch, had found that guinea pigs inoculated with 
cholera bacteria would die even if the bacteria had been heat-killed prior to the 
challenge.  When using other Gram-negative bacteria he could reproduce his results, 
and concluded that the lethality of an infection was not necessarily related to the 
viability of the microorganism. He proposed that death was caused by a formerly 
unknown heat-stable toxic substance from the bacterial “body substance”. When 
realizing the potency of his discovered toxin, Pfeiffer asked with awe, “Was müssen 
das für Substanzen sein, die in so verschwindenden Mengen so starke Wirkungen 
auslösen?” [54]. He termed it “endotoxin”, to simultaneously indicate its toxic potential 
and the inherent association with the bacterial cell. 
Today we know that endotoxin, or LPS, is a structural component of the outer 
membrane of Gram-negative bacteria and one of the most potent inducers of an 
inflammatory immune response in humans. It is this response, rather than the direct 
action of the LPS molecule, which may be harmful to the host in a dose-dependent 
manner. Minute amounts of endotoxin cause a balanced, protective response to a 
microbial challenge, while large doses induce shock and death [55]. Since endotoxin 
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elicits many of the key characteristics of sepsis, such as fever, myalgias, alterations of 
the leukocyte population and shock, it was enticing to assume that sepsis mortality was 
attributable to a similar unbalanced, exuberant immune response. It was even stated that 
“Our arsenals for fighting off bacteria are so powerful,…that we are in more danger 
from them than from the invaders. We live in the midst of explosive devices; we are 
mined.” [56].  
Logically, understanding the biochemical pathways of endotoxin signaling would 
not only provide insights into host-microbial interaction, but also open up routes to 
successful sepsis therapies. Immunology thus became the principal field of research in 
the quest to understand sepsis, and endotoxin was an easily accessible tool for studies 
of a “septic” response, in vitro as well as in vivo. 
 
1.4.1.3 A gruesome forecast: the cytokine storm 
In the 1970s it was shown that macrophages were key effector cells in the host 
response to endotoxin [57]. Also, researchers could identify substances released from 
monocytes/macrophages that independently would reproduce the response to 
endotoxin, indicating the existence of endogenous mediators of endotoxicity [58]. In 
the following years, a plenitude of similar messenger molecules originating from 
immune cells were identified. They were normally produced during a short period in 
response to a stimulus (e.g. LPS), and shared the capacity to induce a range of 
immunomodulatory effects through the activation of specific target cells. These signal 
proteins were termed cytokines, and among the first to be characterized were TNF [58, 
59] and IL-1 [60, 61], both powerful activators of the systemic inflammatory response 
seen in sepsis and endotoxemia, with overlapping and synergistic effects [33, 62]. 
Soon, additional “downstream” cytokines were categorized, like IL-8, which recruits 
and activates neutrophils (such chemotactic cytokines are often referred to as 
chemokines), and IL-6, an inductor of fever and the acute phase response [33] (Fig. 4). 
 
 
 
 
 
FIGURE 4. Pattern of cytokine release after endotoxin administration 
(reprinted from Lowry [158] with permission from Wolters Kluwer Health). 
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The theory of an excessive immune response responsible for death in sepsis was 
now strengthened by a sequence of observations: endotoxin caused profuse secretion of 
proinflammatory cytokines; administration of high doses of these cytokines would, like 
endotoxin, inflict shock and death, while lower doses caused a more moderate 
inflammatory response; circulating TNF was detected in sepsis patients and an 
association between high levels and a poor outcome was demonstrated [62, 63]. 
Finally, antibody-mediated blockade of TNF protected laboratory animals from the 
lethal effects of endotoxin and sepsis [64, 65]. This was very close to a definite proof of 
principle: fatal sepsis was caused by an uncontrolled release of proinflammatory 
cytokines, leading to a cascade of injurious events resulting in irreversible damage to 
vital functions. The term “cytokine storm” was established to describe this process [66], 
and the stage was set for the introduction of innovative therapies striving to temper an 
immune system gone berserk. 
 
1.4.2 In pursuit of new therapies 
 
 
 
 
1.4.2.1 From bench to bedside - a dead end? 
There were, back in the early 1990s, freshly acquired insights into the 
immunological pathways of sepsis. There were new substances, like monoclonal 
antibodies, ready to counteract the effects of specific proinflammatory mediators, in 
order to reverse the cascade of events that caused organ failure. Also, there were new 
sepsis definitions that would allow enrolment of large patient cohorts in clinical trials. 
Finally, there was an enthusiastic pharmaceutical industry, braced by promising results 
from animal and early phase clinical trials. This was the time for large-scale 
randomized placebo-controlled trials. 
Among the first modulators of a proinflammatory response to reach phase III sepsis 
trials were inhibitors of endotoxin, TNF and IL-1. While some of the studies could 
report benefits in subgroups of patients the overall results were disappointing, failing to 
demonstrate reductions in sepsis mortality [67-69] (for the pharmaceutical industry, 
some of the disappointment was probably mitigated by the dramatic success of TNF-
inhibitors in the treatment of chronic inflammatory conditions like rheumatoid arthritis 
and Crohn´s disease, now a billion dollar market).  
Meanwhile, groundbreaking discoveries in the field of innate immunity were 
continuously reported. It was now recognized that the SIRS-inducing, proinflammatory 
response was soon to be followed by a balancing response, mediated by anti-
inflammatory molecules like IL-10 (Fig. 4) and IL-1ra. Also, from previous 
experiments it was known that exposure to endotoxin, in vitro and in vivo, led to a 
drastically diminished immune response to further LPS challenges. This state was 
called “endotoxin tolerance” and was thought to protect the organism from the harm of 
repeated endotoxemia, by a “reprogramming” of leukocytes and a reduced production 
of proinflammatory mediators [70, 71]. A similar down-regulation in monocytes, 
characterized by a reduced expression of the antigen presenting receptor HLA-DR, 
together with an inhibited capacity to secrete proinflammatory cytokines, was also 
demonstrated in human sepsis [72, 73]. Taken together, these data moderated the view 
“And thus the native hue of resolution 
Is sicklied o’er with the pale cast of thought” 
 - William Shakespeare, Hamlet 
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of sepsis as a predominantly hyperinflammatory state. Indeed, it could not be excluded 
that the aggressive anti-inflammatory treatments given in sepsis trials could have 
aggravated an already immunosuppressed condition in large groups of patients, thereby 
possibly eradicating a positive signal from groups that had benefitted from the therapy. 
This led to some self-critical reflection, a reassessment of the sepsis hypothesis, and the 
invention of another acronym, CARS, from some of the authors of the original 
ACCP/SCCM criteria [74]. 
 
 
 
 
 
 
 
1.4.2.2 CARS – a deadly vehicle? 
“Compensatory anti-inflammatory response syndrome” or CARS was one of several 
terms given to the immunosuppressive phase detected in sepsis. Like SIRS, CARS was 
believed to be potentially detrimental when unchecked, presumably through an 
impeded clearance of microbes and increased susceptibility to opportunistic secondary 
infections. The inflammatory response model was modified accordingly, giving rise to 
speculations on novel therapeutic strategies, where immunostimulation by 
proinflammatory agents could play a role (Fig. 5). There was, however, also a furthered 
understanding of the complexity of the disease process [72, 74, 75]. Targeting 
appropriate patient populations, likely to benefit from future immunomodulatory 
interventions, whether pro- or anti-inflammatory, would necessitate reliable markers for 
the monitoring of patients´ inflammatory status [27]. Surprisingly, this contention was 
largely ignored by clinical investigators. The search for a “magic bullet” which 
supposedly would cure a large generic sepsis population, only defined by organ failure 
and SIRS criteria, has consequently continued unabated during the last decades. Until 
now, only one product indicated for the treatment of sepsis, drotrecogin alpha 
FIGURE 5. Imagined pro- and anti-inflammatory systemic immune responses over time during 
severe sepsis/septic shock. The dotted lines represent unbalanced responses leading to death.  
SIRS; systemic inflammatory response syndrome. CARS; compensatory anti-inflammatory 
response syndrome. 
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(activated protein C, an anticoagulant mediator), has reached the market. It was 
recently withdrawn by the manufacturer due to failure to reproduce the initial positive 
results [12]. This persistent lack of success has caused an ongoing debate, where some 
voices advocate a moratorium on clinical sepsis trials until better patient definitions are 
achieved [76], while others suggest promising new candidates for successful 
immunomodulation, albeit with a more personalised approach [43]. 
 
1.4.2.3 Back to basics 
At the turn of the millennium, encouraging advances seen in other high risk 
conditions like multi-trauma, myocardial infarction and stroke were conspicuously 
lacking in the field of sepsis, where mortality remained unacceptably high [77]. In the 
absence of a novel magic-bullet-therapy, attention turned to existing health care 
practices. 
 
1.4.2.3.1 Supportive treatment 
From animal sepsis models it was well known that early interventions were more 
likely to be successful, a treatment strategy which had also significantly reduced 
morbidity and mortality in acute cardiovascular disease and trauma. The term “golden 
hour” was used in trauma care to describe a critical period where timely treatment made 
a difference between life and death. Perhaps it was then only proper that a group of 
emergency care physicians, familiar with the “golden hour” concept, translated it into 
sepsis treatment. In their 2001 landmark report on an aggressive resuscitation approach 
termed “early goal-directed therapy” (EGDT), they aimed to attain a number of 
predetermined hemodynamic goals during the patients´ first 6 hours in the emergency 
department (ED) through the employment of fluids, blood and vasoactive drugs. The 
ultimate goal was to reverse global tissue hypoxia, and the investigators could 
demonstrate a decrease in mortality from 46.5% to 30.5% in patients with severe sepsis 
and septic shock [78]. This impressive result attracted wide attention and shifted, at 
least partly, the focus of sepsis treatment from the intensive care unit (ICU) to the ED.  
While the mortality reduction undoubtedly was notable, the overall mortality rates 
presented in the EGDT study were extremely high regardless of treatment group, thus 
representing a profoundly ill study population. For instance hypoperfusion, as 
illustrated by mean blood lactate levels, was 7.3 mmol/L in the subjects, a greatly 
elevated value even in regard to the severe sepsis limit at 3 mmol/L. Although a 
severely ill population has the advantage of enabling statistically significant differences 
in hard outcome variables like mortality, it also follows that results may not be 
generalizable to, in this case, a wider population of sepsis patients presenting to the ED. 
Indeed, subsequent reports indicated that patients qualifying for EGDT would only 
represent a few percent of these [79, 80]. It seemed like the early treatment protocol 
was actually given to patients in an advanced, late stage of disease. Obviously, 
detection and intervention at an earlier disease stage held considerable promise for 
further reduction of sepsis morbidity and mortality.  
 
1.4.2.3.2 Antimicrobial therapy 
When considering that sepsis was postulated a host response to infection, it is 
perhaps not surprising that it was the area of immunology which attracted most 
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research efforts in the search for new therapies. Also, since the development of modern 
sepsis theory was closely connected to the development of intensive care and the 
emerging capability of lifesaving organ support [81], many of the most influential 
scholars of the field were rooted in intensive care. One might speculate that this 
circumstance caused some attention to be channeled away from the treatment of 
invading microbes toward the treatment of endangered organs.  There was, in any case, 
a notion that antibiotics, although indispensable in treating the underlying infection, 
would not alter the effects of an exuberant inflammatory response, which would require 
specific therapy [23]. The contribution of antibiotic therapy to a reduced mortality had 
been made decades earlier, and was now taken for granted, included as a fixed variable 
in the total sepsis risk equation.  
However, there were a number of factors which helped to reawaken interest in 
antimicrobial therapy. First, after numerous failed immunomodulator trials, this was a 
period of reflection and a return to basic treatment strategies. Second, there were recent 
studies confirming a negative impact on survival when inappropriate antimicrobial 
therapies were given to critically ill patients [82-84]. Third, it was by now evident that 
successful sepsis treatment was threatened by the rising global health problem of 
antimicrobial resistance. Finally, in a seminal article Kumar et al. published compelling 
evidence of the importance of timely administration of appropriate antimicrobials to 
patients with septic shock. Each hour delay in accomplishing administration of 
adequate antibiotics led to an average decrease in survival of 7.6%, and time to 
initiation of effective therapy was the single strongest predictor of outcome [30]. This 
study had some significant implications. Septic shock was established as a “golden 
hour” diagnosis where prompt institution of appropriate antimicrobials was a 
therapeutic cornerstone. Also, it became apparent that effective halting of bacterial 
growth was a sine qua non for the successful reversal of a deleterious host response. 
 
1.5 THE CLINICIAN´S CONDITION 
The sepsis diagnosis is based on an imperfect combination of vital physiological and 
biochemical abnormalities and cultures, none of which per se is specific enough for a 
definitive diagnosis. The clinical picture is notoriously variable and share numerous 
signs and symptoms with several critical conditions, making it particularly susceptible 
to biased decision making. Among critically ill sepsis patients, a misjudgment earlier in 
the continuum of care is a common finding, and a recurring topic of intraprofessional 
discussions and morbidity & mortality rounds. It is obvious that clinicians, experienced 
or not, need to corroborate their clinical decisions with objective data when it comes to 
sepsis.  
Results from cultures are not available until several days and do not contribute to 
clinical decision-making in the acute situation. Under such conditions, additional 
information beyond that which is obtainable from clinical examination is precious. For 
further insight into pathogenesis and prognosis, numerous molecules involved in the 
systemic response to infection have been proposed as biomarkers of sepsis [85]. Most 
of these are still in the experimental state, but a few, like CRP and WBC, have been 
routinely employed in acute care settings for many years, while others, like 
procalcitonin (PCT), have been introduced only recently. LBP, IL-6, soluble triggering 
receptor expressed on myeloid cells-1 (sTREM-1) and heparin-binding protein (HBP) 
are examples of mediators of the innate immune response that have been suggested as 
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sepsis markers, but have not yet made their way into clinical practice [81, 86]. A brief 
description of biomarkers relevant for this thesis is presented below. 
 
1.5.1 Biomarkers of relevance for this thesis 
1.5.1.1 WBC and neutrophils 
White blood cells or leukocytes are protagonists of the inflammatory response and 
were among the first immune cells to be described. Neutrophils form the major part of 
circulating leukocytes and are promptly recruited to an inflammatory site in response to 
infection or tissue damage. Neutrophil demargination and bone marrow mobilization 
result in rapidly increased and readily measurable WBC and neutrophil counts, 
emblematic of an acute systemic inflammation. This effect, however, is a general 
inflammatory reaction and not specific for infections.  
 
1.5.1.2 C-reactive protein 
CRP, one of the first reported acute phase proteins, was described in 1930 as a 
substance in the sera of pneumonia patients which precipitated the C-polysaccharide of 
Streptococcus pneumoniae [87]. Roughly half a century later it was widely adopted as a 
marker of infection in Swedish health care settings. Primarily, CRP production follows 
upon IL-6 activation of hepatocytes. It binds to various structures, among them 
bacterial surfaces, damaged cells and complement. CRP thereby activates the 
complement system and facilitates bacterial opsonization. The fact that plasma levels 
may increase more than a thousandfold within a few days after immune activation 
makes CRP a suitable biomarker for acute care situations. As an acute phase protein, 
CRP production is associated with a number of inflammatory conditions, including 
chronic inflammatory diseases, trauma and pancreatitis. Hence, CRP is not a specific 
marker of infection [33, 88]. 
 
1.5.1.3 Procalcitonin 
PCT as a marker of infection and sepsis was not described until 1993 [89]. A 
precursor of calcitonin, PCT is predominantly produced in the thyroid under 
homeostatic conditions, but may be ubiquitously and rapidly expressed in response to 
various inflammatory challenges. While increased levels of PCT have been reported for 
numerous conditions like trauma, malignancies and pancreatitis, it is suggested to be 
more specifically associated with bacterial infections of a systemic nature than other 
biomarkers. Elevated plasma levels of PCT can be detected within hours after an insult, 
with peak values as soon as after 12-24 h, which is earlier than for CRP.  This kinetic 
profile is considered favourable in the diagnostics of infections at risk of rapid 
progression [81, 90, 91]. 
 
1.5.1.4 Lipopolysaccharide binding protein 
While LPS, component of Gram-negative bacteria and a potent PAMP, had been 
extensively studied for decades, the response protein LBP was not described until 1986 
[92]. LBP is present in the circulation at low levels under normal conditions, but 
increases during the acute phase reaction with a kinetic profile similar to that of CRP. It 
is, like CRP, an acute phase protein, mainly synthesized by hepatocytes in response to 
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IL-1 and IL-6. Since LBP binds to free LPS, it has been proposed as a marker of sepsis 
and Gram-negative infections [33, 81, 93].  
 
1.5.1.5 Interleukin 6 
Cytokines are key regulators of numerous inflammatory responses, and increased 
plasma levels can be detected within hours of an inflammatory insult (Fig. 4). Most 
inflammatory cytokines have been reported in association with sepsis. IL-6, an 
important inducer of the systemic inflammatory response, is mainly responsible for the 
initiation of fever and the acute phase response. As an “upstream” mediator it is 
synthesized and detectable more rapidly than the proteins of the acute phase response, 
thus making it a potentially valuable marker in the earlier stages of sepsis. High levels 
of IL-6 have also repeatedly been reported in association with poor prognosis and organ 
dysfunction [33, 94-97].  Nonetheless, like most mediators of the innate immune 
response, IL-6 can also be triggered by various non-infectious conditions. 
 
1.5.1.6 Cytokine profiling 
Although circulating cytokines have been measured in association with sepsis and 
SIRS for many years, no specific cytokine or combination of cytokines has emerged as 
a reliable marker fit for clinical practice. This may in part depend on the influence of 
circulating soluble receptors and various interactions with plasma proteins, obscuring 
associations of significance for the disease process. For this reason, we speculated that 
an alternative methodological approach could yield more accurate results.  
 
1.5.2 The antibiotic dilemma 
Since administration of adequate antibiotics is urgent, treatment has to be given 
empirically, before culture results are available. The diagnostic uncertainty is 
compensated for by the usage of one or more broad-spectrum antibiotics to patients 
with presumed severe sepsis/septic shock, an approach which also may propel the 
process of escalating antibiotic resistance among bacteria. Thus, on the one hand the 
risk of a deteriorating patient, on the other hand the contribution to growing resistance. 
The second part of this dilemma is easily disregarded at the patient´s bedside, which is 
one of the obvious reasons for the precarious current situation. When there is little 
margin for error, as in the case of a critically ill patient, the scales are tipped in favor of 
unselective, broad antimicrobial therapy.  While point prevalence studies indicate that 
about a third of the patients in a general hospital population are under antibiotic 
treatment [98], this fraction is more than twice as high in the ICU setting [99, 100], 
which has been called an “epicenter for the acquisition and dissemination of antibiotic 
resistance in bacterial pathogens” [101].  
This predicament could, however, be alleviated by better tools for appropriate 
selection of patients with evidence of infection, preferably before progression to a more 
severe stage of disease. We hypothesized that it would be possible to define such a risk 
population through a systematic collection of key clinical variables and biochemical 
data in the early hospital course of patients admitted from the ED with a suspected 
severe infection (Fig. 6).  
Additionally, we imagined it feasible to monitor the inflammatory response in sepsis 
by employing the enzyme-linked immunospot (ELISpot) technique. As opposed to 
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determining the amount of circulating cytokines, ELISpot measures cytokine secretion 
at the very source, the individual cell.  We hypothesized that this “immunological 
snapshot” of cytokine secreting cells could provide a more relevant illustration of the 
association between cytokine release and disease. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 6. Schematic illustration of an ideal distribution of ED patients after appropriate 
examination and competent interpretation of available markers of infection 
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2 AIMS 
 
2.1 GENERAL AIMS 
 
A. To assess the prevalence and clinical impact of severe sepsis and the diagnostic 
value of currently available clinical and biochemical markers in a patient 
population with a suspected serious infection. 
 
B. To increase knowledge of cytokine production at the cellular level in response 
to sepsis and endotoxin through the introduction and evaluation of the ELISpot 
technique in this context. 
 
 
2.2 SPECIFIC AIMS 
 
Paper I To evaluate a number of clinical and laboratory variables measured early 
in the hospital course of patients admitted with a suspected severe 
infection for their ability to identify conditions that require antibiotic 
treatment. Secondary aims were to determine the potential of the same 
variables to detect bacteraemia and severe sepsis. 
 
Paper II To assess the prevalence and clinical impact of severe sepsis in a selected 
ED population with a clinical suspicion of severe infection and, in 
addition, to investigate the association of SIRS criteria with severe sepsis 
and a subsequent critical course. 
 
Paper III To examine cytokine secretion from circulating leukocytes in sepsis, in 
particular in relation to severity and stage of disease. 
 
Paper IV To investigate the cytokine release of different leukocytes in response to 
endotoxin based on the number of producing cells. 
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3 MATERIALS AND METHODS 
 
3.1 SUBJECTS 
 
3.1.1 Paper I-II 
A total of 404 patients at risk for a severe infection who were admitted from the EDs 
at the Karolinska University Hospital (Solna and Huddinge sites) to the Department of 
Infectious Diseases were enrolled prospectively from August 2004 through October 
2005, using convenience sampling. The attending clinicians´ decision to order blood 
cultures and to admit the patient to the ward served as markers for a suspicion of a 
severe infection. Patients with prior participation in the study or age below 18 years 
were excluded.  
The results presented in paper I and II were derived from this patient cohort. 
 
3.1.2 Paper III 
This was a prospective observational study of 32 patients admitted to the Karolinska 
University Hospital (Solna and Huddinge sites) from July 2009 through July 2010, 
using convenience sampling. Patients who were admitted to the hospital and presented 
with signs of sepsis according to consensus criteria [23] were eligible. Exclusion 
criteria were age below 18 years and leukopenia due to hematological disease or 
chemotherapy. Healthy volunteers (n=30) from the hospital staff served as controls. A 
majority of the patients (26/32; 81%) were enrolled from ICUs. 
Nine healthy volunteers were also administered LPS for an experiment of human 
endotoxemia. 
 
3.1.3 Paper IV 
Healthy human volunteers exclusively served as blood donors in this 
methodological study. 
 
 
3.2 METHODS 
 
3.2.1 Data collection (paper I-III) 
3.2.1.1 Paper I-II 
Vital sign data were recorded on admission to the ED and every 4 h for the first 24 h 
at the hospital on a 24h/7d basis: body temperature, heart rate, blood pressure, 
respiratory rate, oxygen saturation (pulse oximetry), urine output, signs of confusion or 
decreased alertness.  
Age, sex, and significant comorbidities (malignancy, chemotherapy, liver disease, 
congestive heart failure, renal failure, chronic obstructive pulmonary disease, diabetes 
mellitus, neurological disorder, transplant, HIV, and substance abuse) were recorded as 
well as time of arrival to the ED, the time of initiation of antimicrobial therapy, length 
of stay at the hospital and 28-day mortality. 
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Blood was drawn on admission from all patients for cultures (at least 10 ml each for 
aerobic and anaerobic cultures), analysis of hemoglobin (Hb), WBC, neutrophil count, 
platelet count, CRP, PCT, IL-6, LBP, lactate, prothrombin time (INR), D-dimer, 
albumin, serum creatinine, urea, bicarbonate, and bilirubin. Results from all 
biochemical analyses were available to the treating clinician, with the exception of 
PCT, IL-6 and LBP. Other cultures and analyses were left to the discretion of the 
treating physician.  
 
3.2.1.2 Paper III 
Data of relevance for diagnoses and severity stratification were retrieved 
retrospectively through chart reviews and from the Patient Database Management 
System (Clinisoft, GE Healthcare) of the participating ICUs. Blood for subsequent 
ELISpot analysis was obtained from patients and controls on inclusion. 
 
3.2.2 Diagnostic criteria and severity stratification (paper I-III) 
We used criteria adapted from sepsis consensus definitions [23, 29] to stratify 
patients according to sepsis severity. To render possible an evaluation of the presence 
of SIRS in relation to severe sepsis in paper II, SIRS was not considered a prerequisite 
for this diagnosis. Severe sepsis was thus defined as a state with organ dysfunction/s 
induced by an acute infection within 24 h of hospital stay in paper I-II. In paper III 
most patients were treated in the ICU and septic shock was defined as severe sepsis 
with hypotension requiring vasopressor therapy or refractory to adequate volume 
resuscitation for >1 hour. We also employed the traditional SIRS criteria for the sepsis 
diagnosis in this study. For further severity stratification we utilized the Sequential 
Organ Failure Assessment (SOFA) and Acute Physiology and Chronic Health 
Evaluation II (APACHE II) scores according to the Swedish Intensive Care Registry 
guidelines [102]. 
 
Final main infectious diagnoses, settled by attending physicians through regular 
diagnostic procedures, were audited independently and retrospectively by two of the 
authors (P.G-J. and B.G.) with the use of predefined diagnostic criteria collected from 
widely published guidelines or similar authoritative sources. Patients with an 
indeterminable diagnosis were exempted from further analyses. 
 
3.2.3 Laboratory methods (paper I-IV) 
Accredited hospital routine methods were used throughout for laboratory analyses. 
Exceptions are listed below. 
 
3.2.3.1 PCT, IL-6 and LBP (Paper I) 
For PCT, IL-6 and LBP discussed in paper I, serum was stored in frozen aliquots at 
-70ºC for later analysis. PCT was analysed with an immunoluminometric assay 
(BRAHMS AG Berlin, Germany), while IL-6 and LBP were analysed with a 
chemoluminiscence immunoreaction method (Imulite, SPC Scandinavia AB, Mölndal, 
Sweden).  
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3.2.3.2 The ELISpot assay (paper III-IV) 
The ELISpot assay is a highly sensitive immunoassay employed for a variety of 
applications to study immune cell responses. Since the ELISpot assay is between 20 
and 200 times more sensitive than conventional enzyme-linked immunosorbent 
assay (ELISA) and allows for detection of cytokines at the single cell level, it is 
particularly suited for cytokine detection in small populations of activated cells and 
may reflect in vivo conditions more accurately. In comparison with ELISA, ELISpot 
measures frequencies of secreting cells as opposed to the total amount of released 
cytokines. Furthermore, the ELISpot assay is dissimilar to techniques using mRNA and 
intracellular staining, in that it exclusively detects actually secreted cytokines.  
ELISpot was used to investigate cytokine secretion (TNF, IL-6, GM-CSF, IL-1β, IL-
12p40, IL-10) from separated leukocytes in paper III, and from PBMC and PMN in 
paper IV (IL-1β, IL-6, IL-8, IL-10, IL-12, TNF, GM-CSF, MIP-1β; in addition IFN-γ,  
perforin and granzyme B were tested in PMN exclusively).  
Ninetysix-well membrane plates were pre-coated with desired specific capture 
antibodies, followed by the introduction of separated cells at predefined cell 
concentrations to wells containing medium, with or without LPS, and incubated for 20 
hours at 37°C in 5% CO2. After incubation, cells were removed by phosphate-buffered 
saline (PBS) washing, and biotinylated detection antibodies binding to captured 
cytokines were added. Subsequently, a streptavidin-alkaline phosphatase conjugate was 
added, which in combination with the final addition of a substrate formed a colored 
precipitate, constituting a visual spot corresponding to one single secreting cell. 
Counting of spots was performed in an ELISpot reader system. The principal steps of 
the assay procedure are illustrated in figure 7. 
 
3.2.3.3 Luminex assay (paper III) 
Plasma levels of the investigated cytokines were analyzed using a kit based on the 
multiplex Luminex technology according to the manufacturer´s instructions. 
 
3.2.3.4 ELISA (paper IV) 
In order to compare ELISpot results to conventional ELISA, LPS-stimulated 
granulocytes were incubated for 20 hours, using uncoated ELISpot plates. Supernatant 
concentrations of IL-6, TNF and IL-1β were subsequently analyzed in pre-coated 
ELISA kits according to the manufacturer’s instructions.  
 
3.2.3.5 Isolation of cells (paper III-IV) 
Freshly collected blood from study subjects served as the source of cells.  
Peripheral blood leukocytes (paper III) were separated by the mixing of equal 
volumes of blood and a 2% dextran PBS solution, where erythrocytes were allowed to 
sediment. The remaining leukocyte buffy coat was collected, and cells were counted 
and centrifuged. The supernatant was removed and stored for later analysis of 
cytokines, while the leukocyte pellet was resuspended in cell culture medium, diluted to 
desired cell concentrations and incubated in ELISpot plates.  
PBMC (paper IV) were isolated by the mixing of equal volumes of blood and PBS, 
where the mixture was layered on Ficoll-Paque PLUS and centrifuged. The PBMC 
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layer was collected and washed twice with cell culture medium. Cells were counted and 
diluted to desired concentrations before entering ELISpot plates. 
Monocytes were, for one experiment, depleted from the PBMC fraction by applying 
anti-human CD14 magnetic particles. After incubation, cells were suspended in cell  
 
 
 
FIGURE 7. Principal steps of the ELISpot  assay procedure 
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culture medium and placed in a magnet device according to the manufacturer´s 
instructions. The unbound cell fraction, depleted of monocytes, was retrieved and 
washed. The depletion procedure was then repeated once. 
PMN (paper IV) were isolated by using the erythrocyte-granulocyte pellet after 
Ficoll separation. After resuspension in PBS to original blood volume, the sample was 
layered on Polymorphprep. After centrifugation the PMN fraction was removed and 
mixed with PBS. Cells were washed twice in cell culture medium and contaminating 
erythrocytes were depleted by hypotonic lysis. Remaining PMN were counted and 
diluted to desired concentrations. Light microscopy and flow cytometry was employed 
to determine the purity of the preparation, which was found to be > 98%. 
Cell viability was controlled via trypan blue exclusion for all extracted cell types. 
 
3.2.4 Statistics (paper I-IV) 
To compare quantitative variables the Mann-Whitney U-test and the unpaired 
Student´s t-test were used, as appropriate. The χ2-test or Fisher´s exact test were applied 
for categorical variables. Correlation analysis (paper III) was performed by Spearman´s 
test. For the comparison of naïve and LPS-stimulated cells in paper IV, Wilcoxon´s 
signed rank test was used. Additionally, for paper I, binary logistic regression was used 
for multivariate analyses and receiver operating characteristic (ROC) analysis was 
employed for the evaluation of diagnostic performance of individual markers. 
A significance level of 0.05 was used throughout. 
 
 
3.2.5 Ethics (paper I-IV) 
All studies were approved by the Regional Ethical Review Board at the Karolinska 
Institute. 
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4 RESULTS AND DISCUSSION 
 
4.1 PAPER I-II 
After ED triage the patients of this study were directed to the infectious disease 
physician on duty, due to a suspected infection. Patients were subsequently admitted to 
the infectious disease department with a preliminary diagnosis of an infection-induced 
illness with a severity that required hospitalization. In the absence of microbial 
confirmation the attending physician relied on the clinical presentation, vital signs, and 
a set of biomarkers for diagnostic and therapeutic guidance. In this cohort, patients with 
a non-infectious final diagnosis evidently presented with symptoms and signs 
consistent with an acute infectious disease.  
In paper I, we evaluated a selection of vital signs and biochemical variables for their 
accuracy to identify a number of clinically relevant conditions within this highly 
selected population. With the exception of PCT, LBP and IL-6, results from 
biochemical analyses were accessible to the admitting clinician. 
In paper II, we assessed the prevalence and clinical impact of severe sepsis in this 
population and the association of SIRS criteria with severe sepsis and a subsequent 
critical course.  
Patients’ characteristics and distribution within the investigated conditions are 
reported in table 1 and figure 8. In the following, the term “organ dysfunction” may 
refer to both hypotension, hypoperfusion and specific organ dysfunctions according to 
the definition, unless otherwise indicated. 
 
 
 
Age; median (range)   61 (18-100) 
Gender male/female 201 (49.8) / 203 (50.2) 
Location prior to admission  
    Long term care facility   29 (7.2) 
    Home 375 (92.8) 
Underlying chronic conditions 157 (38.9) 
Subject to intensive care   18 (4.5) 
Mortality at 28d 
 
 
 
  11 (2.7) 
Length of stay, days; median (range)     4 (1-96) 
Infection requiring antibioticsb 286 (70.8) 
Bacteremia   68 (16.8) 
Severe sepsis 156 (38.6) 
Final diagnosis  
    Respiratory tract 139 (34.4) 
    Urinary tract   63 (15.6) 
    Skin / soft tissue   43 (10.6) 
    Gastrointestinal   27 (6.7) 
    Miscellaneous bacterial   45 (11.1) 
    Nonbacterialc   27 (6.7) 
    Noninfectiousd   26 (6.4) 
    Unevaluable   34 (8.4) 
 
 
 
a
  Data are no. (%) of patients, 
unless  otherwise indicated.  
b  
pneumonia n=128, urinary tract 
n=63, skin/soft tissue n=43, 
abdominal focus n=12, 
endocarditis n=6, orthopedic 
infections n=5, catheter related 
infections n=5, neutropenic fever 
n=5, gastrointestinal n=5, 
bacterial meningitis n=3, dental 
infection n=3 and 2 each of 
bloodstream infection, otitis 
media, upper respiratory tract 
and rickettsial infection 
c  
viral n=25, malaria n=2 
d
  malignancy n=5, pulmonary 
embolism n=4, systemic diseases 
n=3, musculoskeletal disease n=4, 
and 1 each of cerebral infarction, 
myocardial infarction, chronic 
obstructive pulmonary disease, 
Sweet’s syndrome, reactive 
pericarditis, allergic skin reaction, 
reactive arthritis, postoperative 
fever, heart failure and 
postinfectious asthenia 
 
TABLE 1. Patient characteristics paper I-II (N=404)a 
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4.1.1 The vitals 
Patients at risk for imminent deterioration require appropriate interventions urgently. 
Under such circumstances, instantly available information is most valuable, preferably 
at bedside. The four classic vital signs, temperature, heart rate, blood pressure and 
respiratory rate (RR), belong to this category. They are easily controlled repeatedly 
with a minimum of instrumentation and discomfort to the patient. Their contribution to 
a reliable assessment of fundamental physiological functions make them part of most 
hospital monitoring and triage systems [103-105]. In addition to the classic vital signs, 
we also controlled oxygen saturation (pulse oximetry), urinary output, and signs of 
confusion or decreased alertness.  
The vital signs are not disease specific, an advantage when developing severity 
assessment systems based on more generic groups of patients, but a potential drawback 
for a diagnostic tool. For this reason it was interesting that, within this selected 
FIGURE 8. Infections and severe sepsis in enrolled ED patients of paper I-II. 
*Intensive care treatment (n=14) and/or death (n=8) within 28 days 
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population, RR actually contributed significantly to the correct classification of 
infections requiring antibiotic therapy and, also bacteremia. When patients with 
pneumonia were excluded from the analysis, this result was not changed. This was 
contrasting with the other registered vital signs, of which only the initial mean arterial 
blood pressure (MAP) was associated with bacteremia in the univariate analysis, an 
association which was lost in the multivariate analysis. Although sensitivity and 
specificity was modest, the highest registered RR during the first four hospital hours 
yielded a slightly larger area under the ROC curve (AUC) than the RR at presentation, 
which supports the benefit of repeated measurements. Median RR for patients in need 
of antibiotic therapy and bacteremia was, respectively, 24 and 24.5/min (Table 2).  
Temperature, heart rate, and RR also constitute three of the classical SIRS 
parameters, together with WBC (Box 1). Meeting the SIRS criterion of a RR >20 was 
significantly associated with the diagnosis of severe sepsis as well, which was not seen 
for the temperature and heart rate parameters. The median RR for patients with severe 
sepsis was 24/min, equal to that of patients with bacteremia and an infection requiring 
antibiotics.  
In severe sepsis, respiratory dysfunction has been shown to be an early and frequent 
sign of prognostic importance [106-109].  The cytokine driven inflammatory response 
augments body temperature and the global metabolic demand, which together with 
local effects within the respiratory system induces an increase in RR and tidal volume. 
Moreover, hypoperfusion induces acidosis, which also increases alveolar ventilation 
[110, 111]. Several scoring systems intended for various populations have included a 
RR of ≥30 as a cut-off value indicative of severe disease [112-114]. Logically, sepsis 
associated respiratory derangements occur on a continuous scale. Our results suggest 
that, for an ED population at risk of developing a severe infection, an elevated RR 
merits attention also at more moderate levels. Interestingly, a RR of 24/min has been 
suggested as a cut-off level for critical illness, based on data from various hospital 
populations [110]. 
 
 
 
 
 
 
 
 
 
 Need for antibiotics Bacteremia 
Indicator p 
Median (IQR) 
with / without antibiotic need Indicator p 
Median (IQR) 
with / without bacteremia 
WBC (x10
9
/L) 0.001 12.7 (9.2-17.2) /9.0 (7.0-12.6) CRP (g/L) 0.006 231 (81-352.5) /131 (49-228) 
Hemoglobin  (g/dL) 0.002 13.0 (11.6-13.9) / 13.5 (12.5-14.4) Respiratory rate 0.008 24.5 (20-31.5) /22 (18-26.5) 
Respiratory rate  0.005 24 (20-28) /20 (17-24) PCT (μg/L) 0.008 4.1 (0.9-17.2) /0.3 (0.1-1.9) 
CRP (g/L) 0.010 167 (72-273) /60 (18-157) Bilirubin (μmol/l) 0.038 17 (11-25) /13 (9-19) 
 
 
 
 
TABLE 2. Variables independently predicting an infection requiring antibiotics or bacteremia in a  
multivariate logistic regression model 
 
IQR, interquartile range 
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4.1.2 The biomarkers 
4.1.2.1 Infections requiring antibiotic therapy 
In the univariate analysis, elevated levels of WBC, neutrophils, CRP, PCT, IL-6, 
LBP and a reduced Hb were associated with an infection requiring antibiotics. In the 
multivariate analysis, only WBC, Hb and CRP remained as independent predictors.  
In Sweden, both WBC and CRP are established acute markers routinely employed in 
the diagnosing of infections. They are, however, markers of a general inflammatory 
response and not specific to infections. Accordingly, the discriminatory ability was not 
overly impressive, with an AUC of 0.71 for CRP and 0.68 for WBC. The AUC 
difference between CRP and WBC was remarkably small, considering the unparalleled 
confidence the clinicians seemed to confer on CRP for antibiotic prescriptions; the 
decision to actually prescribe antibiotics was significantly associated with the CRP 
result, which was not the case for WBC and Hb. Furthermore, the accuracy of the 
clinician´s antibiotic decision within the first 4 hours was not superior to the accuracy 
of CRP in identifying infections requiring antibiotics. All the other biomarkers, 
however, performed worse, and in anticipation of better markers CRP seems to deserve 
its position as the foremost guide for antibiotic decisions in the emergency care 
environment. It should be kept in mind, though, that the limited discriminatory ability 
leads to substantial overlap between patient groups (Fig. 9), making judgments based 
on individual results uncertain. 
 
 
 
 
 
 
FIGURE 9. Box-plot representing the distribution of CRP results between 
patients with/without antibiotic need 
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Anemia is a common sign of chronic infections and inflammatory conditions [115], 
but a reduced Hb is not generally considered a marker of acute infection. Rather, sepsis 
patients are often hypovolemic on presentation with an expected increase in hematocrit 
and Hb concentration. Contradicting this view, our results suggest that a decreased Hb 
is a significant sign of an acute bacterial infection. This observation is biochemically 
explained by the rapidly altered iron metabolism induced by the inflammatory 
response. IL-6 and LPS trigger the hepatic release of the acute phase protein hepcidin, 
which inhibits duodenal absorption of iron. In addition, uptake of transferrin-bound 
iron into monocytes/macrophages is stimulated. Within hours, this process leads to a 
limited availability of circulating iron, resulting in a functional iron deficiency. The 
evolutionary background to this phenomenon is probably to be found in the microbes´ 
indispensable need for iron as a substrate [33, 48, 115]. 
A number of the investigated biomarkers share an association with the hepatic acute 
phase response; IL-6 as an inducer, CRP and LBP as actual acute phase proteins, and 
Hb as a downstream response protein. Individually, they signaled significant alterations 
in response to infections requiring antibiotics, mirroring the importance of the acute 
phase response as a defense mechanism. Nonetheless, of these proteins only CRP and 
Hb retained an independent ability to predict this condition, Hb with the more modest 
AUC of 0.6, making individual interpretation even more difficult than for CRP and 
WBC. 
PCT has been proposed as a more reliable marker of bacterial infection than CRP 
and other traditional tests [116], and has become increasingly introduced across acute 
care settings in recent years. Interestingly, in the multivariate analysis PCT failed to 
meet the expectations of a significant independent predictor of infections requiring 
antibiotics. There are some results from similar patient cohorts which support this 
finding [117, 118].  
Taken together, we found that an introduction of biomarkers like PCT, LBP and 
IL-6 in the ED would not contribute significant guidance to antibiotic decisions. 
Furthermore, CRP, WBC and Hb provide valuable, but insufficient information for 
these critical judgments. 
 
4.1.2.2 Bacteremia 
“As regards prognosis, it is evident that a negative [blood] culture does not give 
much assistance, while a positive result gives a very unfavorable prognosis in the 
majority of cases” [46]. More than a century of medical development has passed since 
this assertion was published, and it still holds true; bacteremia is consistently a sign of 
severe infection [83, 119-121]. Bacteremic patients constituted a subset to the group of 
subjects with infections requiring antibiotics, and we wished to examine whether there 
were specific markers characterizing this population at risk of critical disease.  
Of the biomarkers, an augmented WBC, neutrophil count, CRP, PCT, IL-6, LBP, 
lactate, D-dimer, urea, bilirubin, and a reduced platelet count was significantly 
associated with bacteremia on presentation. In the multivariate analysis, PCT, CRP and 
bilirubin remained independent predictors. For this condition PCT demonstrated a 
superior diagnostic accuracy; with the AUC of 0.77 it was the best total performance of 
any marker. 
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4.1.2.3 Severe sepsis 
When analyzing the association between the studied variables and the presence of 
severe sepsis within the first 24 h of hospitalization, we excluded variables directly or 
indirectly instrumental in the definition of severe sepsis. Of the remaining variables 
(Hb, CRP, PCT, IL-6 and LBP), only IL-6 and PCT were significantly associated with 
severe sepsis. Thus, regarding discrimination between severe sepsis and other 
conditions in ED patients with a suspicion of severe infection, CRP appears not to be a 
valuable marker in this context. 
 
4.1.2.4 Procalcitonin – a severity marker? 
For this ED population, PCT did not provide valuable guidance on antibiotic 
decisions, but was significantly associated with bacteremia and severe sepsis, both 
potentially critical conditions. CRP did not predict severe sepsis and performed worse 
than PCT for bacteremia.  
In an a posteriori analysis of the PCT distribution between these conditions, a 
picture emerged where PCT primarily seemed to respond to bacteremia. Indeed, the 
least severely ill bacteremic patients, those without severe sepsis, exhibited 
significantly higher PCT values than non-bacteremic patients with severe sepsis 
(p=0.03, data not shown). In fact, of patients without bacteremia only the most severely 
septic, those with multiple organ failure, demonstrated PCT results comparable with 
bacteremic patients without severe sepsis (Fig. 10). Within the bacteremic group, 
increments of sepsis severity were associated with increased PCT results. For non-
bacteremic patients, PCT could not discern between patients without severe sepsis and 
those with severe sepsis and only one organ dysfunction. Thus it would seem as if PCT 
chiefly is a marker of the systemic inflammatory response seen in association with 
bacteremia. This is in line with the results of other authors, who also discuss the usage 
of PCT to exclude bacteremia and limit the number of drawn blood cultures [122-124]. 
Such a measure would have been injudicious in our cohort, as there was a small 
number of bacteremic patients with normal PCT results. Rather, the additional value of 
a single PCT measurement on ED presentation can be questioned, as there is ample 
access to alternative severity markers, e.g. those defining severe sepsis. Certainly, this 
does not preclude the potential success of repeated PCT measurements for monitoring 
purposes and for guidance on antibiotic duration, areas which have seen some 
promising results [125-128]. 
 
4.1.2.5 Notes on biomarkers 
Although we could demonstrate a certain clinical utility for several of the 
investigated markers, it was limited. The ideal sepsis biomarker will provide 
information on the presence or absence of an underlying infection, the nature of the 
infectious insult (viral/bacterial, local/systemic etc.), severity of disease, prognosis, 
therapeutic alternatives and treatment response. Biomarkers exhibiting similar qualities 
have been introduced for other severe diagnoses, e.g. acute myocardial infarction. 
However, unlike distinct organ related conditions with a well characterized pathology, 
sepsis is more of a concept aiming to describe a clinically relevant syndrome. In sepsis, 
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a variety of inherently different pathophysiological processes share the capacity to 
converge in a common clinical phenotype. In addition, the innate immune system reacts 
similarly in response to microbial structures (PAMPs) and endogenous alarmins 
(DAMPs), and establishing markers that reliably distinguish sepsis from SIRS of other 
origin has consequently proven to be a challenge. In summary, it seems unlikely that 
any single biomarker will become the universal sepsis marker. For the present, we will 
have to accept markers of a more narrow capacity, adapted to specific situations or 
conditions.  
In emergency care settings it is of particular importance to distinguish patients at 
risk of imminent progression from those with a more limited disease. Hence, markers 
with an ability to mirror pathophysiological processes responsible for clinical 
deterioration have been of special interest, and for this reason a multitude of substances 
related to vasodilation, endothelial damage, and coagulation dysfunction have been 
tested [85]. So far, success has been limited, but there have been some promising 
reports. A recently discovered molecule associated with monocyte activation, 
sTREM-1, is upregulated in the presence of bacteria and fungi, and has been suggested 
as an important inducer of shock [129]. In clinical studies it has also been reported to 
perform better than CRP and PCT, both for the detection of infections and as a 
prognostic marker [130-132]. However, other authors have reported contradicting 
results in critically ill patients [133], as well as in ED patients with a suspected 
infection [134]. A recent meta-analysis which investigated the predictive ability for 
bacterial infections showed a pooled AUC of 0.91 for sTREM-1, indicating a high 
discriminative capacity [135]. This report did not address the prognostic ability, 
however. 
Another biomarker which has attracted recent attention is HBP, a vasoactive 
mediator released from activated neutrophils. HBP was shown to be highly predictive 
of severe sepsis in a cohort of ED patients similar to the one we studied. With an AUC 
of 0.95, a remarkable performance for a sepsis marker, HBP could also predict 
circulatory failure in 29 of 32 patients hours before the onset of hypotension [86]. In 
subsequent studies of intensive care patients, however, these extraordinary results have 
FIGURE 10. Box-plot representing the distribution of PCT results between patients 
with/without bacteremia. SS, severe sepsis; OF, organ failure 
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not been reproduced, in particular due to a rather poor specificity; it seems as if an 
increase in HBP levels is a more common finding in critically ill patients, regardless of 
infectious status [136, 137]. In addition, in a study of patients with shock, HBP could 
not distinguish between septic and non-septic shock [138]. Therefore, HBP may be a 
more general marker of critical disease. Nonetheless, for a population of ED patients 
with a high pre-test probability of severe infection, HBP appears to be a promising 
candidate marker for severe sepsis, and further validation from larger studies is 
desirable.  
In recent years, several groups have also employed a strategy where information 
from biomarkers representing various aspects of the inflammatory response is 
combined to a more complete picture. With data from plasma concentrations of PCT, 
neutrophil expression of CD64, and sTREM-1, Gibot et al. created a score which 
outperformed all of the individual biomarkers when it came to diagnosing sepsis in 
critically ill patients [139]. For ED patients with suspected sepsis, Shapiro et al. used a 
biomarker panel of neutrophil gelatinase-associated lipocalin (NGAL), IL-1ra, and 
Protein C which was predictive of severe sepsis, septic shock, and death [140]. A 
Danish group evaluated a combination of six markers (CRP, PCT, neutrophils, 
sTREM-1, suPAR and MIF) for the detection of sepsis in a cohort of ED patients, and 
found the combination to be superior to the individual markers [134]. Thus, the 
application of composite markers holds some promise for improved diagnostic 
accuracy, and recent technological progress will provide ample opportunities for future 
studies within this field.  
 
4.1.3 SIRS and severe sepsis 
A closer examination of the prevalence and impact of severe sepsis and SIRS within 
the study population was performed and reported in paper II.  
To make the relationship between SIRS and severe sepsis evaluable, SIRS was not 
considered a prerequisite for the diagnosis of severe sepsis,  which is in accordance 
with current Swedish national sepsis guidelines [141]. Furthermore, we refrained from 
using the diagnosis septic shock, defined as persistent hypotension despite adequate 
volume resuscitation, since the definition is vague, subject to interpretation, and 
difficult to manage outside of the ICU in an environment where continuous monitoring 
of physiological parameters is not always feasible. Hence, all patients with hypotension 
induced by infection were classified as having severe sepsis. 
 
4.1.3.1 SIRS 
Not surprisingly, SIRS (Box 1) was a common finding within this cohort. Of 
patients with at least three registered SIRS parameters at ED presentation, 72% met the 
definition. Between 47% and 65% of the individual criteria were satisfied on 
presentation, the lower rate for RR and the higher for temperature (Fig 11). The 
presence of SIRS on arrival was significantly associated with a final diagnosis of an 
infection requiring antibiotics, but neither with severe sepsis nor severe sepsis with a 
critical course. Interestingly, we found that fulfilment of two of the individual 
 
   35 
 
 
criteria, WBC and RR, actually did correlate significantly with a diagnosis of severe 
sepsis within 24 h, in contrast to the temperature and heart rate criteria. An explanation 
for this could be that fever is a cardinal sign of most acute infections, regardless of 
severity, and thus highly unspecific. In an ED population based on the assumption of an 
infection, a high prevalence of fever is certainly to be expected. Moreover, since 
temperature and heart rate are covariates, patients with a high fever are likely to also 
experience tachycardia, and thus they will, conditionally, meet a second SIRS criterion. 
Hence, the inclusion of interdependent variables in a criterion based diagnosis must be 
regarded as fallacious; such variables should not receive the same weight as 
independent variables, or they will contribute to spurious results. In the case of SIRS, 
this is likely to result in an overly high sensitivity. In our study, a majority of the 
patients satisfied the SIRS definition regardless of the presence of infection, severe 
sepsis or bacteremia. Of patients with severe sepsis and a critical course, this fraction 
was as large as 88%. This result, based on a limited number of patients in our study, 
agrees with data from large ICU studies [28, 142]. To improve specificity, a stricter 
SIRS definition has been applied in some large studies, with a requisite of three 
satisfied criteria instead of two [143, 144]. When using this definition, we obtained a 
significant association between SIRS and severe sepsis, as well as between SIRS and 
severe sepsis with a critical course. Clearly, this involved an increased restrictiveness. 
Even among the critically ill subjects, 24% did not meet this stricter definition, and 
findings from larger series suggest that a large proportion of critically ill infected 
patients will be excluded by a stricter definition [142, 145]. If used in clinical trials, this 
definition will involve a selection bias that will limit the external validity of the results. 
In summary, our results suggest that SIRS status defined on arrival in the ED is a 
both non-discriminatory and potentially restrictive tool of poor value for the 
identification of severe sepsis and prediction of a sepsis associated critical course, a 
view which has been substantiated by similar observations in studies of various 
FIGURE 11. SIRS criteria met by patients on ED presentation, fractions. 
Figures within bars refer to the number of patients represented by the 
bar portion  
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populations [28, 106, 145-148]. It is time for the classical SIRS definition to be 
abolished.  
 
4.1.3.2 Severe sepsis, organ dysfunction and critical course 
There were 110 patients (29.7%) who met the criteria for severe sepsis on ED 
presentation, and after the first 24 h of hospitalization there were in total 156 patients 
(42.1%) who had developed an organ dysfunction, making severe sepsis a common 
condition within this cohort. In the vast majority of cases, the cause was bacterial 
(n=139; 89.1%). Out of seven possible dysfunctions defining severe sepsis 
(hypotension, hypoperfusion, respiratory, neurologic, renal, coagulatory and hepatic), 
no patient had more than four, and a single organ dysfunction was most abundantly 
observed (n= 90; 57.7%). Only 20 (12.8%) of the patients with severe sepsis sustained 
a critical course, defined as either death within 28 days (n=8; 5.1%) or subjection to 
intensive care (n=14; 9.0%). The relations between the number and type of organ 
dysfunctions are illustrated in figure 12 and 13. 
 
 
 
 
 
 
 
Our results suggest that severe sepsis is a common occurrence in patients admitted 
with suspected infections during the first 24 h of hospital stay. The most striking 
observation, however, was the low case-fatality rate (5.1%; 95% CI 1.7-8.6%). 
Traditionally, this figure has been reported to be several times higher for severe sepsis, 
often around 30% or more [3, 8, 10, 144]. This raises some questions with regard to 
heterogeneity between studies. Was this a treatment effect? Or, was our study 
population inherently different from most other populations? If so, how? Was there a 
classification bias?  
FIGURE 12. Number of organ dysfunctions observed in patients with severe sepsis 
and in those who developed a critical course. Figures within bars refer to the 
number of patients represented by the bar portion. Having more than one organ 
dysfunction was significantly associated with a critical course. OR, odds ratio. 
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FIGURE 13. Types of organ dysfunctions observed in patients with severe sepsis and 
in those who developed a critical course. Figures within bars refer to the number of 
patients represented by the bar portion.  
 
When it comes to such a multifaceted syndrome as sepsis, issues like these can be dwelt 
upon at length. For the sake of brevity, this discussion will be restricted to a few 
aspects.  
First, our patients were attended to by infectious diseases physicians, especially 
trained to detect and treat these conditions, which is not the case in most ED settings. 
Did this lead to earlier detection and superior treatment? There may be unrecognized 
data supporting this, but when it came to one important factor, time to antibiotics, this 
was not the case. The median time to antibiotic therapy was 2.25 h from presentation, 
not better than what has been reported in ED studies with higher mortality [149, 150].  
Second, this was a study addressing an ED population, while most sepsis studies 
historically have been performed in ICU settings, where mortality rates generally are 
higher than in other hospital contexts. Nevertheless, one of the raisons d´être for the 
present sepsis definitions was improved generalizability between studies [23]. If the 
occurrence of intensive care is an inherently better marker of severity than what can be 
inferred from the sepsis definitions per se, then we must ask ourselves to what extent 
they are purposeful. It may be that the severe sepsis criteria better define a population at 
risk of, rather than established critical disease, which is the case for ICU patients.  
The definitions of severe sepsis are dichotomous; any of a number of organ failures 
will satisfy the diagnostic criteria. Furthermore, once an organ dysfunction criterion is 
met, subsequent grading of the dysfunction is not supported. Within the field of 
intensive care, this issue has been negotiated by the establishment of severity scoring 
systems, e.g. the SOFA score, once introduced for the assessment of sepsis induced 
organ failures [151].  The SOFA score has demonstrated a fairly good accuracy of 
mortality prediction also in the ED, and has been suggested as an additional tool for 
risk stratification and prognostication of ED patients with severe sepsis [152]. While 
we did not apply the SOFA score in this study, it may be worth considering for future 
studies.  
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Third, the greater part of severe sepsis patients in our cohort only had one organ 
dysfunction, of whom only 8% suffered a critical course. On the other hand, the most 
common dysfunction was hypotension, a marker of global systemic failure associated 
with poor outcome [153]. Most of our patients, however, responded to fluids and 
hypotension was a transient phenomenon. Also, the presence of hypotension was not 
significantly predictive of a critical course when compared to other organ dysfunctions.  
While hypotension can be described as a marker of macrocirculatory failure, 
hypoperfusion, as represented by hyperlactatemia, is considered a marker of deranged 
microcirculation resulting in tissue hypoxia. In the last decade, lactate has emerged as a 
preeminent prognostic marker among the sepsis defining criteria [11, 78, 153-155]. 
There were relatively few of the patients in our study who presented with 
hyperlactatemia. Of those, however, 35% sustained a critical course. This proportion 
was higher than for other organ dysfunctions, albeit not significantly. It cannot be 
excluded though, that the low overall incidence of hypoperfusion was representative of 
a less critically ill population. 
Finally, the devil is in the details, and when it comes to sepsis, the definitions. In 
reviewing a substantial number of previously published studies for their respective 
definitions of severe sepsis, a great variety among the definitions used, pertaining to 
both SIRS and the various organ dysfunctions, was noted. Selected examples 
 
 
 
Hypotension Hypoperfusion Respiration CNS Renal Coagulation 
SBP<90 or 
MAP<70 ≥1h 
despite fluids 
pH ≤7.30 or BE≥-5 
and 
Lactate>1,5x 
ref.max 
PaO2/FiO2 
<280(mmHg) 
Acute 
altered 
mental 
status 
(GCS<14) 
<0,5ml/kg/h  
for 1h 
Platelets low or 
↓>25% 
+ ↑INR+↑APT or 
bleeding 
SBP<90 >1h 
despite fluids 
Lactate>2 mmol/l PaO2<70mmHg  
(air) 
PaO2/FiO2 
<280(mmHg) 
Acute 
altered 
mental 
status 
Creatinine ≥300 
µmol/l 
or < 500 ml/d 
Platelets<100 
SBP<90 or ↓40 pH ≤7.30 or 
Lactate>2,5 
RF>24  
or ventilator 
GCS≤11 <0,5ml/kg/h for 
≥2h despite fluids 
Platelets<100or 
↓>50% or INR>2 or 
↑APT≥20% 
SBP<90 or ↓40 
>1h despite 
fluids 
Lactate> ref.max 
orBE≥-5 or pH<7,3 
PaO2≤75mmHg  
(air) 
PaO2/FiO2 
≤250(mmHg) 
↓GCS≥2p <30 ml/h for ≥1h 2 of: 
A. Platelets<75 or 
↓>50% 
B. INR>1,5 
C. D-dimer 
>0.5orFDP>10  
MAP<70 ≥0,5h 
despite fluids 
Lactate>2 mmol/l 
orBE>-5 
PaO2/FiO2 
<300(mmHg) 
 
GCS≤9 <0,5ml/kg/h 
for 2h despite 
fluids or Creatinine 
↑>45 µmol/l 
Platelets<150 
 
 
 
 
TABLE 3. Examples of organ dysfunction definitions from various sepsis studies. 
SBP, systolic blood pressure; MAP, mean arterial blood pressure; BE, base excess; PaO2, partial arterial oxygen 
pressure; FiO2, fraction of inspired oxygen; RF, respiratory frequence; GCS, Glasgow coma scale 
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are presented in table 3. All studies referred to either the 1992 or the 2001 consensus 
definitions, sometimes with the addition “modified from”, or a similar wording. 
Furthermore, numerous studies do not report their organ dysfunction criteria in detail. 
Thus minor variations within seemingly identical definitions could potentially 
constitute heterogeneous study populations, influencing observed frequencies of, e.g., 
severe sepsis and sepsis attributed mortality. Indeed, this was recently illuminated by a 
Dutch group that applied various definitions used in earlier landmark studies to their 
own ICU population. The range of observed incidences of severe sepsis varied 
substantially with the definitions used, between 6 and 27% [156]. To this should be 
added considerable diversity in the definitions of infection between studies, varying 
from microbiologically confirmed to clinically suspected with antibiotic treatment. Our 
definitions may have been at the milder end of the organ dysfunction spectrum, thus 
limiting the case fatality rate. In fact, one large sepsis ED study using similar 
definitions reported a severe sepsis mortality of 9.2% [106]. This was still nearly twice 
ours, although this difference could probably be attributed to dissimilar background 
populations, sheer random variation, or a combination thereof.  
In my view, a set of definitions similar to the ones we used may well be appropriate 
for the discrimination of infected patients at risk of progression to a more critical stage 
of disease. As a whole, however, the field of clinical sepsis research is in urgent need of 
more precise and unambiguous definitions. In the 2001 revision of the consensus 
definition of sepsis the so-called PIRO concept was launched [29]. This theory 
recognized the shortcomings of the original definition, and proposed a novel multi-
dimensional approach, seeking to characterize predisposing (P) factors like comorbidity 
and genetic polymorphisms; the insult (I), i.e. the nature of the infectious source; the 
pathophysiological and immunological response (R); and the extent of organ 
dysfunctions (O). After more than a decade, the PIRO model remains a beautiful 
hypothesis in search of practical applications, and it will take tremendous efforts to 
develop it into a useful and validated tool for research and clinical practice. Yet, in 
recent years we have seen unprecedented advances in areas like gene expression 
profiling, proteomics, nanotechnology, and techniques for microbial detection. Through 
these methods we may gain a more sophisticated understanding of underlying 
mechanisms, hopefully sufficient for the construction of more accurate definitions and 
interventions for the clinical phenotype we refer to as sepsis. 
 
 
4.2 PAPER III 
Cytokines are fundamental to the coordination of the inflammatory response. During 
sepsis, these proteins abound in plasma and most pro- and anti-inflammatory cytokines 
have been associated with a critical course [94]. Still, no cytokine has stood the test of a 
clinically relevant marker, and the role and origin of circulating cytokines remain 
incompletely elucidated. We hoped to clarify whether blood dwelling leukocytes 
express cytokines during sepsis by using the sensitive ELISpot technique, which 
measures the number of actively cytokine secreting cells instead of the circulating 
amount of cytokines. We also aimed to explore whether the secretion pattern would 
provide a more accurate and clinically useful representation of the disease process. 
Blood from sepsis patients and healthy controls was sampled and transported to the 
laboratory in a timely fashion for the immediate initiation of the ex vivo ELISpot 
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analysis, while plasma was reserved for cytokine measurement by Luminex 
methodology.  
 
4.2.1 Spontaneous cytokine secretion in sepsis and endotoxemia 
Most patients were critically ill, 24 out of 32 (75%), suffered from septic shock, and 
18 (56%) had bacteremia. In such critically ill patients, endotoxemia is a common 
phenomenon [157], and it was reasonable to anticipate high levels of circulating 
PAMPs in this cohort. Somewhat to our surprise, the resulting numbers of 
spontaneously cytokine secreting cells were very low overall, with the largest number 
seen for TNF-secreting cells. There were, however, no significant differences in the 
number of secreting cells between patients and controls for any of the investigated 
cytokines. This lack of in vivo activated, cytokine secreting cells in the circulation was 
evident even in patients with ongoing bacteremia, and irrespective of the interval 
between the first signs or symptoms of sepsis and blood sampling (9-337 h). In 
contrast, plasma levels of the examined cytokines were elevated in sepsis patients, as 
expected (Fig. 14).  
Since the so-called “cytokine storm” in sepsis is believed to be an early 
phenomenon, we hypothesized that the cells might have been exhausted or in a 
compensatory dormant state at the time of blood sampling. For this reason we 
employed a model of human endotoxemia to trigger a “septic” state in healthy 
volunteers, enabling us to study the earliest phase of cytokine secretion after TLR 
activation. In blood collected before and at 30 and 150 min after LPS injection, results 
were consistent with the previous results; there were few or no cytokine secreting cells. 
On the other hand, we found plasma concentrations of TNF and IL-6 to be substantially 
elevated at 150 min. At the same time we observed a notable monocytopenia, 
characterized by a 95% reduction from baseline.  
In summary, we can conclude that regardless of bacteremia, endotoxemia, sepsis 
stage or presence of circulating cytokines, there were few or no actively secreting cells 
in samples from the bloodstream. Our findings suggest that the origin of plasma 
cytokines in sepsis and endotoxemia is not to be found in the population of circulating 
leukocytes. The rapid reduction of monocyte counts seen after LPS injection is a 
familiar phenomenon [158] which probably represents a programmed egress by 
activated monocytes into tissue after an inflammatory stimulus [159]. Plasma cytokines 
most likely are produced by such extravasated monocytes, or possibly by resident tissue 
macrophages. This is an interesting finding since models for ex vivo and in vitro 
analyses of blood cells are frequently used for the exploration of intra- and intercellular 
pathways of the innate immune response. Our results suggest that interpretations 
regarding the cytokine kinetics seen in sepsis should be made with caution when based 
on data from studies of circulating leukocytes, as these cells do not appear to contribute 
to this process. 
An alternative explanation to the negative results could be that the collecting of 
blood and subsequent handling of cells for the ex vivo analysis could have “shut down” 
the sampled cells, leading to false negative results. There are some data that contradict 
this hypothesis. First, in a supplementary experiment we exposed whole blood from 
healthy volunteers to comparable LPS concentrations ex vivo, after which cell 
separation and ELISpot analysis detected cytokine secreting cells of a contrastingly 
high frequency. Second, once the cellular process of transcription, synthesis and 
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secretion of cytokines has been instigated, mechanisms that reverse this process seem 
to be equally complex, primarily aiming at transcriptory inhibition, a time consuming 
process [160]. Third, as discussed below, we applied a “second hit” model, in which the 
cells were exposed to endotoxin ex vivo, which led to significantly increased numbers 
of cytokine secreting cells from both patients and volunteers, thus exhibiting a 
sustained secretory capacity (Fig. 15). 
 
  
FIGURE 14. ELISpot analysis and plasma cytokine concentrations of IL6, TNF-α, IL-1β, 
GM-CSF, IL-10 and IL-12p40 in sepsis patients and healthy controls.  Each graph displays 
spontaneous and LPS-induced cytokine secretion expressed as spots/1000 monocytes 
and plasma concentrations as pg/ml. Data is shown as individual values and horizontal 
bars indicate the median value for each group. 
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4.2.2 Cytokine secretion after ex vivo LPS stimulation  
After exposure to endotoxin, a notable proliferation of cytokine secreting cells was 
observed in samples from both patients and controls. Interestingly, the cells from sepsis 
patients showed a selective down-regulation of GM-CSF, IL-1β, IL-10 and IL-12p40 
after ex vivo LPS stimulation in comparison with the healthy controls. This was not the 
case for TNF and IL-6 producing cells, where similar numbers were observed between 
the groups.  
Subsequent to an inflammatory response, whether induced by infection, trauma or 
experimentally, a resulting hypo-responsiveness of immune cells or organisms to 
further immune stimulation is commonly observed. This phenomenon, often referred to 
as “endotoxin tolerance”, is believed to be a protective measure by which the organism 
balances the deleterious consequences of a protracted inflammatory response. 
Accordingly, monocytes from sepsis patients have been shown to express reduced 
amounts of a vast array of cytokines in response to endotoxin, among them TNF and 
IL-6 [70, 71, 73, 161]. This appeared contradictory to our findings, where the TNF and 
IL-6 secreting capacity of monocytes from sepsis patients was preserved, in contrast to 
the other investigated cytokines. Thus, we concluded that the downregulation of 
cytokine secretion appears to be selective, sparing TNF and IL-6, at least with respect 
to the number of secreting cells. This was an unexpected finding, and the cause of this 
observation remains undisclosed. Nevertheless, due to methodological differences our 
results were not necessarily incompatible with earlier reports of a diminished 
production of these cytokines. While ELISpot is a very sensitive method for the 
detection of secreting cells, it does not quantify the amounts of secreted cytokines. For 
this reason the number of cytokine secreting cells does not necessarily correlate with 
the amounts of cytokine secreted. Also, it should be emphasized that ELISpot detection 
of secreted cytokines is inherently different from “upstream” measurement of 
intracellular synthesis by methods like gene-expression and intracellular staining, 
which may lead to divergent results. 
 
 
 
 
 
 
FIGURE 15. Examples of IL-6, TNF-α and IL-1β spots generated with leukocytes from one 
healthy control and one sepsis patient in the ELISpot assay. Cells were incubated in the 
presence of LPS (2 ng/ml) or cell culture medium alone. 
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4.2.3 Clinical correlation 
As mentioned earlier, the evolution of intensive care during the last century has 
brought the successful treatment of previously lethal diseases within the range of 
possibility. Although there is undoubtedly a potentially life-threatening early pro-
inflammatory phase of sepsis [63], mortality is today more common among patients 
who, with the help of supportive care, have survived this initial stage [43, 162]. In 
addition, it has been increasingly recognized that the modulating anti-inflammatory 
response (“CARS”) is not following upon the initial proinflammatory phase (“SIRS”) 
in a two-wave pattern; it is rather a parallel process where anti-inflammatory cytokines 
like IL-10 are detectable soon after an endotoxin challenge [158], as well as in early 
septic shock [163, 164]. It has recently been shown that also TNF, key instigator of the 
proinflammatory response, induces tolerance to endotoxin in macrophages [165].  
Whether this prompt downregulation of the immune defence is mainly beneficial or 
deleterious is the topic of an ongoing scholarly discussion. On the one hand, there is 
evidence of a compartmentalization of the immune response, where the blood stream 
represents an immunosuppressive milieu with desensitized immune cells, while cells of 
other compartments display a retained or even increased reactivity [166, 167]. This is 
thought to favour containment of an infectious focus, while the systemic response is 
tuned to a less aggressive mode. On the other hand, sepsis-induced immunosuppression 
is believed to be responsible for an impaired clearance of microorganisms, reactivation 
of latent viruses and a reduced resistance to secondary opportunistic infections [168]. 
Indeed, a persistently reduced monocyte HLA-DR expression has been predictive of 
both mortality [169] and nosocomial infections in septic shock [170], while autopsy 
studies have shown that immune cell anergy is not confined to the blood compartment 
in sepsis [171]. Consequently, immunostimulatory therapies with the potential to 
reverse this suppressed state have become a hot topic, although with a more cautious 
approach in view of the disappointing experiences from previous immunomodulator 
trials [172]. The need for correct determination and stratification of patients´ immune 
status is now recognized, and functional testing of monocytes has been suggested as 
one of several tools suitable for this purpose [173]. For this reason we wanted to assess 
the capacity of cytokine secretion from sepsis patients with regard to disease severity 
and stage of disease. Whether measured by sepsis category (shock vs. non-shock), 
SOFA score or APACHE II score, we found no correlations with the plasma levels of 
cytokines. In contrast, we observed significantly fewer monocytes from patients with 
higher SOFA scores secreting GM-CSF, IL-1β, IL-10 and IL-12p40 in response to LPS 
stimulation ex vivo (Fig. 16). Similar differences were found between patients with and 
without septic shock. With respect to TNF and IL-6 secretion, there were, as previously 
found, no significant differences. We concluded that the degree of sepsis-induced organ 
failure, as measured by the SOFA score, was indeed reflected in the degree of failure to 
secrete certain cytokines at the single cell level.  
 
 44 
 
 
 
 
 
Accurate assessment of the sepsis-associated Response is one of the cornerstones of 
the aforementioned PIRO-model. Grading of patients´ current immune status is likely 
to become an important part of this. Due to the multifaceted nature of sepsis-induced 
immunosuppression [168], simultaneous gauging of several immune functions may be 
required, including tests of monocyte responsiveness. Our results indicate that 
measurement of the cytokine secreting capacity at the single-cell level may contribute 
favorably to this end, although further validation from larger-size studies is warranted. 
It is to be noted, however, that the value of this measure is largely dependent on 
whether abnormal findings are amenable to treatment, and further, whether this will 
ultimately improve patients´ outcome. Otherwise, this will be just another severity 
marker of limited clinical utility. 
 
 
4.3 PAPER IV 
This was a preparatory study for the subsequent work on sepsis patients (paper III). 
It was designed to answer basic questions regarding the cytokine secreting repertoire of 
leukocytes participating in the innate immune response to infection.  
We hypothesized that the ELISpot method, which detects individual cytokine 
secreting cells, would more accurately determine the cytokine profile of PMN and 
PBMC than the commonly used ELISA method, which measures the total amount of 
secreted cytokines in cell supernatants. The latter approach is more susceptible to the 
influence of occasional contaminating cells; addition of a few high producing cells, like 
monocytes, to a population of low producers, e.g. granulocytes, may skew the results. 
In contrast, with the ELISpot technique any cytokine producing cell will be represented 
by no more than one spot, thus minimizing the risk of significant influence from 
individual contaminating cells. 
A panel of 8 cytokines (IL-1β, IL-6, IL-8, IL-10, IL-12, TNF, GM-CSF and 
MIP-1β) was tested. In addition, PMN secretion of IFN-γ, perforin and granzyme B 
was analyzed. Cells from healthy donors were cultured in medium alone or stimulated 
by LPS in parallel experiments.  
 
FIGURE 16. ELISpot results for IL-12p40 and GM-CSF demonstrating a significant 
negative correlation between LPS induced cytokine secretion and SOFA score. 
rs, Spearman´s rank correlation coefficient 
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4.3.1 Cytokine release from mononuclear cells 
In PBMC preparations we found relatively high spontaneous secretion of IL-8, 
MIP-1β, and (to a lesser extent) TNF in comparison with the other cytokines. 
Stimulation by LPS induced significantly increased frequencies of secreting cells for all 
the tested cytokines except IL-8, an important chemokine (chemotactic cytokine) 
predominantly responsible for the recruitment of neutrophils to the site of 
inflammation. Instead, larger and denser IL-8 spots were formed in response to LPS, 
plausibly representative of an augmented secretion from individual cells. 
Monocytes are considered the main producers of cytokines among blood cells [174]. 
They constitute a minority of about 10-30% of PBMC, while the lymphocyte family 
forms the absolute majority. To also characterize the cytokine secreting ability of non-
monocytes, we depleted the PBMC population of monocytes via magnetic CD-14 
ligation, and repeated the former experimental procedure. For all the investigated 
cytokines, the secreting cell populations were reduced by 91-99% after LPS 
stimulation, confirming the role of monocytes as supreme cytokine producers. 
 
4.3.2 Cytokine release from polymorpohonuclear cells 
Neutrophils are the frontline soldiers of the immune defense and the most prevalent 
of all leukocytes, normally constituting over 90% of PMN. They share their phagocytic 
capacity with monocytes and macrophages, but unlike these they are known to produce 
only modest amounts of cytokines. Nonetheless, human neutrophils have been reported 
to produce a wide variety of cytokines, some of which are surrounded by controversy 
[175, 176]. This is exemplified by a lack of consensus in the literature regarding the 
neutrophil ability to produce IL-6 and IL-10 [176]. Variations in the purity of cell 
preparations and the concomitant risk of monocyte contamination have been suggested 
as a source of conflicting results [176, 177]. When we explored the secreting capacity 
of isolated PMN, we found evidence of spontaneous secretion of the chemokines IL-8 
and MIP-1β, albeit to a lower degree than in PBMC populations. In response to LPS 
stimulation, the frequencies of IL-8 and MIP-1β secreting cells increased significantly, 
while low numbers of TNF secreting cells also emerged. There were no cells found to 
secrete IL-10, IL-12, GM-CSF, IFN-γ, perforin or granzyme B. Furthermore, there 
were only occasional spots representing IL-6 and IL-1β secreting cells. These spots 
appeared very similar to those produced by PBMC, suggesting monocyte 
contamination. A few similarly large and dense TNF spots, clearly distinct from the 
majority of weaker TNF spots produced by PMN, reinforced this impression. From 
these observations we inferred that the PMN cytokine repertoire is restricted to a few 
cytokines. This finding is supported by others using highly purified PMN separations 
[37, 178].  
 
4.3.3 ELISA versus ELISpot in polymorphonuclear cells 
The ELISpot technique was also compared to ELISA for the detection of TNF, IL-6 
and IL-1β in PMN. With regard to the number of cells needed to detect cytokine 
secretion, we found ELISpot to be more sensitive by a factor of at least ten. As a matter 
of interest, we found a discrepancy between the number of secreting cells detected by 
ELISpot and the amount of cytokines found by ELISA. Based on our previous findings, 
the observation of the highest number of spots for TNF was expected, as was the low 
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number of observed IL-6 and IL-1β secreting cells. Conversely, the highest cytokine 
concentration detected by ELISA was found for IL-6, followed by IL-1β and TNF. We 
suggest that this may be due partly to the contamination of occasional high-producing 
monocytes, partly to cytokine interaction with cell-bound and soluble receptors in 
supernatants after secretion. 
In summary, we found ELISpot to be a useful tool for cytokine detection in various 
leukocyte populations. In addition, we confirmed that monocytes possess the main 
cytokine secreting capacity among blood cells and, finally, that the cytokine arsenal of 
PMN appears to be limited to a few cytokines. 
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5 MAIN FINDINGS 
 
 For a selected population of ED patients with a high pre-test probability of a 
severe bacterial infection we concluded that an increased level of the routinely 
tested markers CRP, WBC, RR and a decreased Hb level contributed 
independently to an accurate selection of patients for antibiotic therapy.  
 The more novel markers PCT, IL-6 and LBP did not confer additional 
information for an antibiotic decision.  
 The diagnostic accuracy was poor for all of the tested biomarkers. 
Consequently, there is a compelling need for better markers in order to facilitate 
antibiotic decisions and to strengthen antibiotic stewardship. 
 PCT proved to be the best severity marker, independently associated with both 
bacteremia and, to a lesser extent, with severe sepsis. 
 Severe sepsis was found to be of frequent occurrence among these patients 
(42%), while mortality was low (5%) in comparison to previous reports. 
 The classical SIRS definition was met by a majority of the patients and did not 
contribute to the classification of sepsis. It should be abolished. 
 By using the sensitive ELISpot technique we could conclude that circulating 
leukocytes are not the source of the elevated plasma levels of cytokines seen in 
sepsis. 
 There was a selective sepsis-induced downregulation of the cytokine secretion 
in response to LPS stimulation ex vivo, reflected in decreased numbers of IL-1 , 
IL-10, IL-12p40 and GM-CSF secreting cells, while the number of TNF and IL-
6 secreting cells remained similar. 
 The reduced number of cytokine secreting cells correlated with disease severity 
as measured by SOFA-score, underscoring the link between disease progression 
and immune status. 
 In blood from healthy donors we confirmed that monocytes are the principal 
cytokine releasing cells, while neutrophil release was restricted to only a few 
cytokines.  
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6 FINAL REFLECTIONS 
 
 
 
 
 
 
More than anything, this work has taught me how challenging and elusive the field 
of sepsis is. To my mind, more far-reaching and comprehensive conclusions are 
difficult to draw from our findings. However, when looking at the individual pieces, 
there are a few points I would like to make which may be of some relevance. 
 
Our observations suggest that, for ED patients with a suspected infection, the 
traditionally used biomarker CRP provides a better basis for an accurate antibiotic 
decision than the highly marketed PCT. The legitimate demand for better biomarkers, 
coupled with the constant discoveries of new candidate molecules and commercial 
interests, may result in an exaggerated enthusiasm. Therefore, it is important that the 
introduction of new biomarkers for predefined patient populations is preceded by 
appropriate validation studies. In addition, the purpose of the test should be well 
defined. Although a truism, this has not always been the case.  
 
It seems obvious that the present sepsis definitions, designed to cure heterogeneity 
and poor generalizability between studies, do not fulfill their purpose. It has been 
repeatedly shown that the 1992 SIRS definition lacks discriminative ability, now also 
by us. Yet, it is still widely used as an inclusion criterion, probably for one reason only: 
everybody else does the same thing. This is not a valid argument. In addition, diffusely 
defined organ dysfunction criteria make the sepsis definitions subject to interpretation, 
leading to variations between studies which hamper the external validity. More detailed 
definitions and standardized inclusion criteria are required to improve our chances of 
developing better therapies and biomarkers. 
 
Even with more strict definitions, the multifaceted clinical phenotype of sepsis is the 
result of various underlying pathophysiological mechanisms.  To enable specific, 
biologically tailored interventions, these processes need to be properly distinguished. 
As a part of this quest, we chose to explore immune cell signaling by employing the 
ELISpot method. We found that circulating leukocytes were not the source of the 
increased levels of plasma cytokines. We also showed that the sepsis-induced 
downregulation of the cytokine secreting ability appeared to be restricted to some 
cytokines but not to others. These findings point to some topics apt for future 
investigations. While circulating blood cells are easily accessible, they may not be as 
relevant to the disease process as cells from other compartments. Efforts should be 
made to enable the study of cells from other locales in sepsis, in particular from 
infectious foci. Furthermore, by simultaneously applying several methods, e.g. flow 
cytometry and mRNA quantification in addition to ELISpot, a more complete picture of 
the subtle mechanisms that regulate cell signaling in sepsis may emerge. As this 
knowledge accumulates, we will eventually be able to delineate and address the distinct 
“When you know a thing, to hold that you know it; and when you do not 
know a thing, to allow that you do not know it - this is knowledge.” 
 - Confucius 
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pathological processes which share the capacity to induce sepsis. This will allow the 
current sepsis definitions to be disassembled and replaced by better validated and more 
relevant disease descriptions.   
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7 POPULÄRVETENSKAPLIG SAMMANFATTNING 
 
7.1 BAKGRUND 
Sepsis, i dagligt tal blodförgiftning, är en allvarlig sjukdom med ett ofta 
fortskridande förlopp. Sjukdomen klassificeras vanligen utifrån tre stadier av ökande 
svårighetsgrad, "sepsis", "svår sepsis" och "septisk chock". De svårare formerna anses 
orsakade av ett överdrivet kraftigt immunsvar vid svåra infektioner. Detta leder till en 
frisättning i blodet av en mängd ämnen, bl a en grupp signalproteiner som kallas 
cytokiner, som gemensamt orsakar kärlläckage, lågt blodtryck och organsvikt. 
Paradoxalt nog anses denna överreaktion snabbt kunna förbytas i en obalans åt andra 
hållet, med ett skadligt försvagat immunförsvar som resultat.  
Antalet fall av sepsis i västvärlden (Europa och USA) kan, lågt räknat, beräknas till 
mer än 2 miljoner fall årligen av vilka en tredjedel har svår sepsis eller septisk chock. 
Dödligheten inom denna tredjedel varierar mellan olika studier, men är fortsatt hög, c:a 
25-50%. Det är klart visat att tidig behandling i sepsisförloppet påverkar utgången. En 
snabb upptäckt av tillståndet är därför av yttersta vikt. Resultaten från bakterieodlingar 
kommer inte förrän efter flera dagar medan vanligt förekommande blodanalyser 
visserligen uppfyller krav på snabbhet men inte är konklusiva och främst tjänstgör som 
stöd i den kliniska bedömningen. Samtidigt bidrar onödig antibiotikabehandling till den 
ökande globala resistensutvecklingen bland sjukdomsalstrande bakterier. Det finns 
således ett stort behov av ny diagnostik för att på ett snabbt och säkrare sätt identifiera 
såväl de patienter som är på väg in i ett livshotande tillstånd, som de som inte har 
antibiotikakrävande infektioner. 
 
7.2 PROJEKTBESKRIVNING 
A. Kritisk granskning av det diagnostiska värdet av ett antal kliniska och kemiska 
markörer i en grupp patienter med hög risk att utveckla svår sepsis. 
 
Sammanlagt undersöktes 404 patienter som lades in på infektionskliniken från 
Karolinska universitetssjukhusets akutmottagning med en misstänkt allvarlig infektion. 
Resultaten redovisades i delarbete I och II. 
I det första arbetet utvärderades förmågan hos ett antal mätningar av basala 
fysiologiska kroppsfunktioner och blodprover att identifiera antibiotikakrävande 
infektioner, bakterieväxt i blodet och svår sepsis.  
Sammanfattningsvis konstaterades att ett antal väletablerade prover (C-reaktivt 
protein, antal vita blodkroppar, hemoglobinhalt) och mätning av andningsfrekvensen 
kan hjälpa läkaren till ett korrekt antibiotikabeslut, men att tillförlitligheten hos dessa 
prover är otillräcklig. Samtidigt kunde nyare inflammatoriska prover (procalcitonin, 
interleukin-6 och lipopolysackarid-bindande protein) inte bidra till denna diagnos. 
Dock var procalcitonin överlägset C-reaktivt protein i diagnostiken av de mer allvarliga 
tillstånden svår sepsis och bakterieväxt i blodet.  
 
I det andra arbetet kartlades förekomsten av svår sepsis hos patienterna och dess 
påverkan av det kliniska utfallet (vårdnivå och dödlighet inom 28 dygn). De variabler 
som definierar det s k system-inflammatoriska svarssyndromet (SIRS), som anses 
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föregå en fortskridande sepsissjukdom, analyserades också i relation till det kliniska 
förloppet. Dessa variabler utgörs i korthet av onormal temperatur, förhöjd puls, förhöjd 
andningsfrekvens, samt en onormal nivå av vita blodkroppar. Två av dessa fyra 
kriterier skall uppfyllas för att kunna ställa diagnosen SIRS.  
Av patienterna uppfyllde 30% kriterier för svår sepsis redan på akutmottagningen. 
Efter 24h hade denna andel ökat till 42%. Endast en mindre andel patienter med svår 
sepsis (13%) utvecklade ett kritiskt förlopp, definierat som intensivvårdsbehov eller 
död inom 28 dygn. Dödligheten var endast 5%, en internationellt sett låg siffra.  
Vid ankomst till akutmottagningen uppfyllde 72% av patienterna definitionen för 
SIRS. Någon betydande skillnad avseende förekomst av SIRS återfanns inte mellan 
patienter som hade/utvecklade svår sepsis och övriga, inte heller mellan patienter med 
svår sepsis med ett kritiskt förlopp och övriga.  
Vi konstaterar att svår sepsis är ett vanligt tillstånd inom det första vårddygnet hos 
patienter som läggs in med misstanke om en allvarlig infektion, men att både 
intensivvårdsbehovet och dödligheten är relativt låga. Vidare att SIRS-diagnosen är ett 
dåligt instrument för att urskilja och förutsäga svår sepsis. 
 
B. Introduktion och utvärdering av ELISpot-tekniken inom sepsisområdet för att 
öka kunskapen om cytokinproduktionen på cellnivå vid sepsis.  
 
ELISpot är en känslig metod för att upptäcka cytokinfrisättning från immunceller. 
Vi hoppades att genom denna teknik kunna få en ”ögonblicksbild” av 
cytokinproduktionen vid sepsis. 
Resultaten av detta projekt har redovisats i delarbete III och IV. 
 
I det tredje arbetet undersöktes sammanlagt 32 patienter med olika grader av sepsis 
inneliggande på Karolinska universitetssjukhuset. Som kontrollpersoner användes 
friska frivilliga från sjukhuspersonalen (30 st.). ELISpot-metoden användes för att 
analysera både spontan frisättning av cytokiner från vita blodkroppar och frisättning 
efter retning av dessa blodkroppar med endotoxin, även kallat LPS, ett bakterieämne 
som vanligen orsakar en kraftig reaktion hos både immunceller och organismer. 
Parallellt undersöktes halten av cytokiner i blodet.  
Trots att halten cytokiner i blodet var påtagligt förhöjd hos sepsispatienterna jämfört 
med kontrollpersonerna, var andelen cytokinfrisättande vita blodkroppar låg och 
likartad mellan patienter och kontrollpersoner. Vi konstaterade därför att vita 
blodkroppar i blodcirkulationen inte förefaller vara ursprunget till de förhöjda 
cytokinnivåer som uppmätts i blodet under sepsis. Dessa cytokinproducerande celler 
finns istället sannolikt i vävnaden och närmare beskrivning av sepsissjukdomen utifrån 
mätning av cytokinutsöndring från vita blodkroppar i blodcirkulationen verkar inte låta 
sig göras. 
LPS-stimulering av de vita blodkropparna åtföljdes däremot av en betydande ökning 
av antalet cytokinproducerande blodkroppar hos bägge grupperna. Medan denna 
ökning var likartad mellan patienterna och kontrollpersonerna för två av cytokinerna 
(IL-6 och TNF), var den betydligt lägre för de övriga fyra undersökta cytokinerna 
(GM-CSF, IL-1β, IL-12p40 och IL-10) inom sepsisgruppen. Graden av nedsatt 
utsöndringsförmåga vid LPS-aktivering befanns sammanhänga med sjukdomsgraden. 
Detta skulle eventuellt kunna användas som en markör för graden av immunhämning 
vid sepsis. 
 52 
Sammanfattningsvis förefaller nedregleringen av cytokinfrisättning att vara selektiv 
vid sepsis, eftersom vissa cytokiner berörs men inte andra, samtidigt som den står i 
proportion till sjukdomsgraden för de nedreglerade cytokinerna. 
 
Det fjärde delarbetet var en förberedande laboratoriestudie inför delarbete III. Här 
undersöktes förmågan hos vita blodkroppar att utsöndra cytokiner efter 
endotoxinretning. De vita blodkropparna uppdelades i de olika undergrupperna 
segmentkärniga (granulocyter) och enkelkärniga (monocyter och lymfocyter) celler. 
Det är väl känt att de enkelkärniga vita blodkropparna står för den huvudsakliga 
cytokinproduktionen, medan granulocytens möjligheter till cytokinsignalering är mer 
omdebatterad, med motstridiga resultat från olika studier. Genom att använda ELISpot-
metoden fann vi att granulocyterna hade en begränsad cytokinarsenal, bland de 
undersökta cytokinerna fann vi endast sekretion av IL-8, MIP-1β och TNF. Vi 
konstaterade också att tidigare rapporterade granulocyt-associerade cytokiner sannolikt 
kan tillskrivas förorening av ett fåtal monocyter. 
De enkelkärniga cellerna utsöndrade som förväntat betydligt fler cytokiner och 
också av en större mängd. När vi separerade monocyter från de övriga enkelkärniga 
cellerna fann vi att antalet cytokinutsöndrande celler reducerades med över 90 procent. 
Vi kunde således konstatera att monocyterna står för den absoluta huvuddelen av den 
cytokinutsöndrande förmågan hos vita blodkroppar. 
 
Sammantaget visar dessa studier: 
 
 vilka tillgängliga laboratorieprover vi bör kunna använda oss av för att på ett 
så tillförlitligt sätt som möjligt kunna diagnosticera allvarliga 
antibiotikakrävande infektioner och besläktade tillstånd hos patienter på 
infektionsakuten 
 ett stort behov av nya diagnostiska tester för att kunna nå bättre resultat och 
kunna säkra en fortsatt tillgång till en hotad antibiotikaresurs 
 att svår sepsis är ett vanligt tillstånd hos patienter som läggs in på 
infektionskliniken, men att diagnosen inte förefaller vara lika allvarlig som i 
andra rapporterade sammanhang 
 att den s k SIRS-diagnosen bör överges 
 att vita blodkroppar i blodcirkulationen inte utsöndrar de cytokiner som finns 
i blodet vid sepsis 
 att de vita blodkropparnas förmåga att utsöndra vissa cytokiner försämras vid 
sepsis i proportion till sjukdomsgraden 
 en närmare beskrivning av enskilda vita blodkroppars förmåga att utsöndra 
cytokiner 
 
Vår förhoppning är att dessa observationer i viss mån skall kunna bidra till ett 
förbättrat beslutsunderlag för läkare som bedömer och behandlar allvarligt 
infektionssjuka patienter i sin vardag, men också utgöra grund för fortsatt forskning 
inom sepsisområdet. 
 
  
 
 
   53 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 54 
8  ACKNOWLEDGEMENTS 
 
I would like to express my sincere gratitude to all who contributed to the completion of 
this endeavour.  Especially I wish to thank: 
 
Bengt Gårdlund – associate professor, senior colleague, consultant, scientist, sepsis 
expert, farmer, hunter (how do you manage it all?) and friend, for your willingness to 
embark on this journey together with me.  Along with your truly impressive knowledge 
of sepsis in theory and in practice, your kind support and patience have been essential 
for this thesis. Also, I would like to thank you for sharing enjoyable moments at 
congresses, in bars and in the woods. When this is over, next time in the woods, OK?   
 
Jan Andersson – professor and outstanding scientist, for your very generous 
acceptance of me as your PhD student. Our meetings have always been rewarding and 
your brilliant brain-storming and benevolent enthusiasm have fuelled me more than I 
think you are aware of. 
 
The rest of our SAMBIO 2006 funded research group:  
Christian Smedman, black belt in the ELISpot technique, for teaching me the ELISpot 
assay (no belt for me), for good companionship and cooperation, and for somehow 
making me feel like I am your age – not a bad experience. Staffan Paulie for discreet 
wisdom and helpful distinctness, and for proposing the joint project. Lindvi 
Gudmundsdotter for your kind assistance and your capacity to get things done. You 
catalyzed us. Anna Somell for good cooperation and for recruitment of patients. Last, 
but certainly not least, Kopek Nihlmark , without whom this project would never have 
come about. Undoubtedly one of the more profitable cocktail chats I have ever had, 
Kopek. Thank you for that and the following coordination of our project, which also 
included some relieving private conversations. 
 
My old friend Gunnar Sandersjöö who invited Kopek and me to the same party and 
provided the cocktails. 
 
All patients and volunteers without whom this work would not have been possible. 
 
Colleagues and staff at the Department of Infectious Diseases who generously donated 
their blood and served as healthy controls. 
 
The staff at the Department of Infectious Diseases, the Emergency Department, and the 
Intensive Care units at Karolinska University hospital for kind assistance in enrolment 
procedures and sampling of blood and data. Your positive attitude and constant 
readiness to do a little bit more is fundamental to the clinical research, let alone the 
patients.  
 
My colleague Karin Hansson for planning and starting the Emergency Department 
study together with Bengt and me. 
 
Research nurse Gunilla Herman for efficient assistance with data base inclusion and 
patient enrolment.  
 
   55 
Professor Kristina Broliden for letting us use your lab resources, for good advice and 
because you saw solutions where I saw problems.  
 
The staff at the Haematology section of the Department of Clinical Chemistry for 
generously providing expertise and resources.  
 
My mentor and friend Li Tsai, for being there the one time I needed you. 
 
Mitchell Shiller, M.D. for altruistically checking the language of the greater part of 
this thesis manuscript. Any remaining errors are my own. 
 
Former heads of the Department of Infectious Diseases, Elda Sparrelid and Jan 
Carlson for allowing me time off from clinical duties for research. 
 
Lennart Östlund for finding rostering solutions that work in spite of the constant 
shortage of physicians. Pure wizardry. 
 
Spotify for helping me endure. 
 
Vinnova, the Swedish foundation for Strategic Research (SSF), The Research 
Council (VR), Bert von Kantzows foundation, Pfizer, and the regional agreement 
on medical training and clinical research (ALF) for financial support.  
 
All senior colleagues who taught me the tricks of the trade and served as role models- 
thank you.  
All colleagues who share the ups and downs of our clinic with passion and good 
humour – it never gets boring. 
 
All my many dear friends for distractions, inspiration and moral support, just a few of 
you mentioned here: 
The Gourmet brothers, you have known me since ages and formed me as a person. By 
the way – who´s next? 
The Tuesday floorball gang – it´s so nice to blow off some steam together with you 
guys. 
The hunters of Löfvik –the serenity, the meditation, the adrenalin, the companionship. I 
am aching to get back. 
The Wine boys and the Book girls – what a great bunch you are, our treks together are 
legendary. A small group of people hiking in pristine nature, philosophizing together – 
a primordial pleasure. 
 
Family and relatives, for being there, for being who you are, and for letting me be 
who I am.  
My dear mother Kerstin for once planting the idea that I could become a physician, 
and for all the marvellous support to my family over the years.  
My mother-in-law Ami for equally superb support. 
Simon, Sebastian and Pelle for making me a very proud father. 
Lastly, the sun of my solar system, my mainstay, my love, my friend, my wife Ann for 
your inexhaustible patience and never-ending love. 
 
 
 
 56 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   57 
9 REFERENCES 
 
1. Of the Epidemics 
 [Internet]. 2012 [cited February 7, 2013]. Available from: 
http://en.wikisource.org/w/index.php?title=Of_the_Epidemics&oldid=3739540. 
2. Gaieski DF, Edwards JM, Kallan MJ, Carr BG. Benchmarking the incidence 
and mortality of severe sepsis in the United States. Crit Care Med. 
2013;41(5):1167-74. 
3. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. 
Epidemiology of severe sepsis in the United States: analysis of incidence, 
outcome, and associated costs of care. Crit Care Med. 2001;29(7):1303-10. 
4. Dombrovskiy VY, Martin AA, Sunderram J, Paz HL. Rapid increase in 
hospitalization and mortality rates for severe sepsis in the United States: a trend 
analysis from 1993 to 2003. Crit Care Med. 2007;35(5):1244-50. 
5. Wilhelms SB, Huss FR, Granath G, Sjoberg F. Assessment of incidence of 
severe sepsis in Sweden using different ways of abstracting International 
Classification of Diseases codes: difficulties with methods and interpretation of 
results. Crit Care Med. 2010;38(6):1442-9. 
6. Harrison DA, Welch CA, Eddleston JM. The epidemiology of severe sepsis in 
England, Wales and Northern Ireland, 1996 to 2004: secondary analysis of a 
high quality clinical database, the ICNARC Case Mix Programme Database. 
Crit Care. 2006;10(2):R42. 
7. Martin GS. Sepsis, severe sepsis and septic shock: changes in incidence, 
pathogens and outcomes. Expert review of anti-infective therapy. 
2012;10(6):701-6. 
8. Beale R, Reinhart K, Brunkhorst FM, Dobb G, Levy M, Martin G, et al. 
Promoting Global Research Excellence in Severe Sepsis (PROGRESS): lessons 
from an international sepsis registry. Infection. 2009;37(3):222-32. 
9. Sundararajan V, Macisaac CM, Presneill JJ, Cade JF, Visvanathan K. 
Epidemiology of sepsis in Victoria, Australia. Crit Care Med. 2005;33(1):71-
80. 
10. Flaatten H. Epidemiology of sepsis in Norway in 1999. Crit Care. 
2004;8(4):R180-4. 
11. Levy M, Dellinger R, Townsend S, Linde-Zwirble W, Marshall J, Bion J, et al. 
The Surviving Sepsis Campaign: results of an international guideline-based 
performance improvement program targeting severe sepsis. Intensive Care 
Med. 2010;36:222 - 31. 
12. Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, et al. 
Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med. 
2012;366(22):2055-64. 
13. Opal SM, Garber GE, LaRosa SP, Maki DG, Freebairn RC, Kinasewitz GT, et 
al. Systemic Host Responses in Severe Sepsis Analyzed by Causative 
Microorganism and Treatment Effects of Drotrecogin Alfa (Activated). Clinical 
Infectious Diseases. 2003;37(1):50-8. 
14. Opal SM, Laterre PF, Francois B, LaRosa SP, Angus DC, Mira JP, et al. Effect 
of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe 
sepsis: the ACCESS randomized trial. JAMA. 2013;309(11):1154-62. 
15. Geroulanos S, Douka E. Historical perspective of the word “sepsis”. Intensive 
Care Medicine. 2006;32(12):2077-. 
 58 
16. Majno G. The ancient riddle of sigma eta psi iota sigma (sepsis). The Journal of 
infectious diseases. 1991;163(5):937-45. 
17. Johansson I, Lynøe N. Medicine & philosophy : a twenty first century 
introduction Heusenstamm: ontos verlag; 2008. 
18. Sagnér A. Livets tjänare. 3rd ed. Malmö: Bengt Forsbergs förlag; 1964. 
19. "Septikemi" [Internet].  [cited Sept. 15, 2013]. Available from: 
http://g3.spraakdata.gu.se/saob/. 
20. Oxford English Dictionary. "sepsis, n.": Oxford University Press. 
21. Van Arsdale WW. I. On the Present State of Knowledge in Bacterial Science in 
Its Surgical Relations (Continued): Sepsis. Annals of surgery. 1886;3(4):321-
33. 
22. Matot I, Sprung CL. Definition of sepsis. Intensive Care Med. 2001;27 Suppl 
1:S3-9. 
23. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. 
Definitions for sepsis and organ failure and guidelines for the use of innovative 
therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. 
American College of Chest Physicians/Society of Critical Care Medicine. 
Chest. 1992;101(6):1644-55. 
24. Trzeciak S, Zanotti-Cavazzoni S, Parrillo JE, Dellinger RP. Inclusion criteria 
for clinical trials in sepsis: did the American College of Chest 
Physicians/Society of Critical Care Medicine consensus conference definitions 
of sepsis have an impact? Chest. 2005;127(1):242-5. 
25. Vincent JL. Dear SIRS, I'm sorry to say that I don't like you. Crit Care Med. 
1997;25(2):372-4. 
26. Opal SM. The uncertain value of the definition for SIRS. Systemic 
inflammatory response syndrome. Chest. 1998;113(6):1442-3. 
27. Cohen J, Guyatt G, Bernard GR, Calandra T, Cook D, Elbourne D, et al. New 
strategies for clinical trials in patients with sepsis and septic shock. Crit Care 
Med. 2001;29(4):880-6. 
28. Alberti C, Brun-Buisson C, Burchardi H, Martin C, Goodman S, Artigas A, et 
al. Epidemiology of sepsis and infection in ICU patients from an international 
multicentre cohort study. Intensive Care Med. 2002;28(2):108-21. 
29. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 
SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. 
Crit Care Med. 2003;31(4):1250-6. 
30. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al. Duration 
of hypotension before initiation of effective antimicrobial therapy is the critical 
determinant of survival in human septic shock. Crit Care Med. 
2006;34(6):1589-96. 
31. Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K, et al. 
Hydrocortisone therapy for patients with septic shock. N Engl J Med. 
2008;358(2):111-24. 
32. Guntupalli K, Dean N, Morris PE, Bandi V, Margolis B, Rivers E, et al. A 
phase 2 randomized, double-blind, placebo-controlled study of the safety and 
efficacy of talactoferrin in patients with severe sepsis. Crit Care Med. 
2013;41(3):706-16. 
33. Mölne J, Wold A. Inflammation. Stockholm: Liber; 2007. 
34. Cinel I, Opal SM. Molecular biology of inflammation and sepsis: a primer. Crit 
Care Med. 2009;37(1):291-304. 
35. van der Poll T, Opal SM. Host-pathogen interactions in sepsis. Lancet Infect 
Dis. 2008;8(1):32-43. 
   59 
36. Rittirsch D, Flierl MA, Ward PA. Harmful molecular mechanisms in sepsis. 
Nat Rev Immunol. 2008;8(10):776-87. 
37. Schroder AK, von der Ohe M, Kolling U, Altstaedt J, Uciechowski P, Fleischer 
D, et al. Polymorphonuclear leucocytes selectively produce anti-inflammatory 
interleukin-1 receptor antagonist and chemokines, but fail to produce pro-
inflammatory mediators. Immunology. 2006;119(3):317-27. 
38. Kantari C, Pederzoli-Ribeil M, Witko-Sarsat V. The role of neutrophils and 
monocytes in innate immunity. Contributions to microbiology. 2008;15:118-46. 
39. Schouten M, Wiersinga WJ, Levi M, van der Poll T. Inflammation, 
endothelium, and coagulation in sepsis. J Leukoc Biol. 2008;83(3):536-45. 
40. Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med. 
2010;38(2 Suppl):S26-34. 
41. Serruto D, Rappuoli R, Scarselli M, Gros P, van Strijp JAG. Molecular 
mechanisms of complement evasion: learning from staphylococci and 
meningococci. Nat Rev Micro. 2010;8(6):393-9. 
42. Abraham E, Singer M. Mechanisms of sepsis-induced organ dysfunction. Crit 
Care Med. 2007;35(10):2408-16. 
43. Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a novel 
understanding of the disorder and a new therapeutic approach. The Lancet 
Infectious Diseases. 2013;13(3):260-8. 
44. Angus DC, van der Poll T. Severe Sepsis and Septic Shock. New England 
Journal of Medicine. 2013;369(9):840-51. 
45. Kuhn TS. The structure of scientific revolutions. 4th ed. Chicago: University of 
Chicago Press; 2012. 
46. White FW. CULTURES FROM THE BLOOD In SEPTICÆMIA, 
PNEUMONIA, MENINGITIS AND CHRONIC DISEASES. The Journal of 
experimental medicine. 1899;4(3-4):425-50. 
47. Dethlefsen L, McFall-Ngai M, Relman DA. An ecological and evolutionary 
perspective on human–microbe mutualism and disease. Nature. 
2007;449(7164):811-8. 
48. Mandell GL, Bennett JE, Dolin R, Kelvin GV, editors. Mandell, Douglas, and 
Bennett's principles and practice of infectious diseases. 7. ed. Philadelphia: 
Elsevier, Churchill Livingstone; 2010. 
49. Esper AM, Moss M, Lewis CA, Nisbet R, Mannino DM, Martin GS. The role 
of infection and comorbidity: Factors that influence disparities in sepsis. Crit 
Care Med. 2006;34(10):2576-82. 
50. Nobelprize.org. Emil von Behring - Biographical: Nobel Media; 2013 [cited 
2013 July 5]. Available from: 
http://www.nobelprize.org/nobel_prizes/medicine/laureates/1901/behring-
bio.html. 
51. Nobelprize.org. Ilya Mechnikov - Biographical: Nobel Media; 2013 [cited 2013 
July 7]. Available from: 
http://www.nobelprize.org/nobel_prizes/medicine/laureates/1908/ehrlich-
bio.html. 
52. Kaufmann SHE. Immunology's foundation: the 100-year anniversary of the 
Nobel Prize to Paul Ehrlich and Elie Metchnikoff. Nat Immunol. 2008;9(7):705-
12. 
53. Metschnikoff E. Ueber den Kampf der Zellen gegen Erysipel-kokken. Archiv f 
pathol Anat. 1887;107(2):209-49. 
54. Rietschel ET, Cavaillon JM. Endotoxin and anti-endotoxin. The contribution of 
the schools of Koch and Pasteur: life, milestone-experiments and concepts of 
 60 
Richard Pfeiffer (Berlin) and Alexandre Besredka (Paris). J Endotoxin Res. 
2002;8(1):3-16. 
55. Beutler B, Rietschel ET. Innate immune sensing and its roots: the story of 
endotoxin. Nat Rev Immunol. 2003;3(2):169-76. 
56. Thomas L. Germs. New England Journal of Medicine. 1972;287(11):553-5. 
57. Moore RN, Goodrum KJ, Berry LJ. Mediation of an endotoxic effect by 
macrophages. Journal of the Reticuloendothelial Society. 1976;19(3):187-97. 
58. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An 
endotoxin-induced serum factor that causes necrosis of tumors. Proceedings of 
the National Academy of Sciences of the United States of America. 
1975;72(9):3666-70. 
59. Beutler B, Greenwald D, Hulmes JD, Chang M, Pan YC, Mathison J, et al. 
Identity of tumour necrosis factor and the macrophage-secreted factor 
cachectin. Nature. 1985;316(6028):552-4. 
60. Dinarello CA, Goldin NP, Wolff SM. Demonstration and characterization of 
two distinct human leukocytic pyrogens. The Journal of experimental medicine. 
1974;139(6):1369-81. 
61. Dinarello CA, Renfer L, Wolff SM. Human leukocytic pyrogen: purification 
and development of a radioimmunoassay. Proceedings of the National Academy 
of Sciences of the United States of America. 1977;74(10):4624-7. 
62. Remick DG, Ward PA. EVALUATION OF ENDOTOXIN MODELS FOR 
THE STUDY OF SEPSIS. Shock. 2005;24 Supplement(1):7-11. 
63. Waage A, Halstensen A, Espevik T. Association between tumour necrosis 
factor in serum and fatal outcome in patients with meningococcal disease. 
Lancet. 1987;1(8529):355-7. 
64. Beutler B, Milsark IW, Cerami AC. Passive immunization against 
cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. 
Science. 1985;229(4716):869-71. 
65. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, et al. Anti-
cachectin/TNF monoclonal antibodies prevent septic shock during lethal 
bacteraemia. Nature. 1987;330(6149):662-4. 
66. Clark IA. The advent of the cytokine storm. Immunology and cell biology. 
2007;85(4):271-3. 
67. Arndt P, Abraham E. Immunological therapy of sepsis: experimental therapies. 
Intensive Care Med. 2001;27 Suppl 1:S104-15. 
68. Marshall JC. Such stuff as dreams are made on: mediator-directed therapy in 
sepsis. Nat Rev Drug Discov. 2003;2(5):391-405. 
69. Vincent JL, Van Nuffelen M. Septic shock: new pharmacotherapy options or 
better trial design? Expert Opin Pharmacother. 2013;14(5):561-70. 
70. Cavaillon JM, Adib-Conquy M. Bench-to-bedside review: endotoxin tolerance 
as a model of leukocyte reprogramming in sepsis. Crit Care. 2006;10(5):233. 
71. Biswas SK, Lopez-Collazo E. Endotoxin tolerance: new mechanisms, 
molecules and clinical significance. Trends Immunol. 2009;30(10):475-87. 
72. Volk HD, Reinke P, Krausch D, Zuckermann H, Asadullah K, Muller JM, et al. 
Monocyte deactivation--rationale for a new therapeutic strategy in sepsis. 
Intensive Care Med. 1996;22 Suppl 4:S474-81. 
73. Munoz C, Carlet J, Fitting C, Misset B, Bleriot JP, Cavaillon JM. Dysregulation 
of in vitro cytokine production by monocytes during sepsis. J Clin Invest. 
1991;88(5):1747-54. 
74. Bone RC, Grodzin CJ, Balk RA. Sepsis: a new hypothesis for pathogenesis of 
the disease process. Chest. 1997;112(1):235-43. 
   61 
75. Bone RC. Immunologic dissonance: a continuing evolution in our 
understanding of the systemic inflammatory response syndrome (SIRS) and the 
multiple organ dysfunction syndrome (MODS). Ann Intern Med. 
1996;125(8):680-7. 
76. Cohen J, Opal S, Calandra T. Sepsis studies need new direction. The Lancet 
Infectious Diseases. 2012;12(7):503-5. 
77. Friedman G, Silva E, Vincent JL. Has the mortality of septic shock changed 
with time. Crit Care Med. 1998;26(12):2078-86. 
78. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, et al. Early 
goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl 
J Med. 2001;345(19):1368-77. 
79. Ho BC, Bellomo R, McGain F, Jones D, Naka T, Wan L, et al. The incidence 
and outcome of septic shock patients in the absence of early-goal directed 
therapy. Crit Care. 2006;10(3):R80. 
80. Shapiro NI, Wolfe RE, Moore RB, Smith E, Burdick E, Bates DW. Mortality in 
Emergency Department Sepsis (MEDS) score: a prospectively derived and 
validated clinical prediction rule. Crit Care Med. 2003;31(3):670-5. 
81. Reinhart K, Bauer M, Riedemann NC, Hartog CS. New approaches to sepsis: 
molecular diagnostics and biomarkers. Clinical microbiology reviews. 
2012;25(4):609-34. 
82. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment 
of infections: a risk factor for hospital mortality among critically ill patients. 
Chest. 1999;115(2):462-74. 
83. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of 
inadequate antimicrobial treatment of bloodstream infections on patient 
outcomes in the ICU setting. Chest. 2000;118(1):146-55. 
84. Harbarth S, Garbino J, Pugin J, Romand JA, Lew D, Pittet D. Inappropriate 
initial antimicrobial therapy and its effect on survival in a clinical trial of 
immunomodulating therapy for severe sepsis. The American journal of 
medicine. 2003;115(7):529-35. 
85. Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit Care. 
2010;14(1):R15. 
86. Linder A, Christensson B, Herwald H, Bjorck L, Akesson P. Heparin-binding 
protein: an early marker of circulatory failure in sepsis. Clin Infect Dis. 
2009;49(7):1044-50. 
87. Tillett WS, Francis T. SEROLOGICAL REACTIONS IN PNEUMONIA 
WITH A NON-PROTEIN SOMATIC FRACTION OF PNEUMOCOCCUS. 
The Journal of experimental medicine. 1930;52(4):561-71. 
88. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 
2003;111(12):1805-12. 
89. Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High 
serum procalcitonin concentrations in patients with sepsis and infection. Lancet. 
1993;341(8844):515-8. 
90. Meisner M. Procalcitonin - Biochemistry and Clinical Diagnosis. Bremen: 
UNI-MED; 2010. 
91. Becker KL, Snider R, Nylen ES. Procalcitonin assay in systemic inflammation, 
infection, and sepsis: clinical utility and limitations. Crit Care Med. 
2008;36(3):941-52. 
92. Tobias PS, Soldau K, Ulevitch RJ. Isolation of a lipopolysaccharide-binding 
acute phase reactant from rabbit serum. The Journal of experimental medicine. 
1986;164(3):777-93. 
 62 
93. Anderson R, Schmidt R. Clinical biomarkers in sepsis. Frontiers in bioscience 
(Elite edition). 2010;2:504-20. 
94. Cavaillon JM, Adib-Conquy M, Fitting C, Adrie C, Payen D. Cytokine cascade 
in sepsis. Scand J Infect Dis. 2003;35(9):535-44. 
95. Oberholzer A, Souza SM, Tschoeke SK, Oberholzer C, Abouhamze A, Pribble 
JP, et al. Plasma cytokine measurements augment prognostic scores as 
indicators of outcome in patients with severe sepsis. Shock. 2005;23(6):488-93. 
96. Bozza FA, Salluh JI, Japiassu AM, Soares M, Assis EF, Gomes RN, et al. 
Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis. 
Crit Care. 2007;11(2):R49. 
97. Mera S, Tatulescu D, Cismaru C, Bondor C, Slavcovici A, Zanc V, et al. 
Multiplex cytokine profiling in patients with sepsis. APMIS. 2011;119(2):155-
63. 
98. Strama. Stramas  Punktprevalensstudier (PPS)  2003-2010 2011 [cited 2013 
Sept 30]. Available from: 
http://www.smi.se/upload/antibiotikastatistik/slutenvard/bildspel-med-statistik-
fran-stramas-PPS-2003-2010.pdf. 
99. Vincent J, Rello J, Marshall J, et al. INternational study of the prevalence and 
outcomes of infection in intensive care units. JAMA. 2009;302(21):2323-9. 
100. Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, et al. 
Sepsis in European intensive care units: results of the SOAP study. Crit Care 
Med. 2006;34(2):344-53. 
101. Opal SM, Calandra T. Antibiotic usage and resistance: Gaining or losing 
ground on infections in critically ill patients? JAMA. 2009;302(21):2367-8. 
102. Svenska Intensivvårdsregistret-SIR. Riktlinjer  [cited 2013 Sept. 29]. Available 
from: http://www.icuregswe.org/sv/Riktlinjer/. 
103. Goldhill DR, McNarry AF. Physiological abnormalities in early warning scores 
are related to mortality in adult inpatients. British journal of anaesthesia. 
2004;92(6):882-4. 
104. Ghanem-Zoubi NO, Vardi M, Laor A, Weber G, Bitterman H. Assessment of 
disease-severity scoring systems for patients with sepsis in general internal 
medicine departments. Crit Care. 2011;15(2):R95. 
105. Subbe CP, Slater A, Menon D, Gemmell L. Validation of physiological scoring 
systems in the accident and emergency department. Emerg Med J. 
2006;23(11):841-5. 
106. Shapiro N, Howell MD, Bates DW, Angus DC, Ngo L, Talmor D. The 
association of sepsis syndrome and organ dysfunction with mortality in 
emergency department patients with suspected infection. Ann Emerg Med. 
2006;48(5):583-90, 90 e1. 
107. Kenzaka T, Okayama M, Kuroki S, Fukui M, Yahata S, Hayashi H, et al. 
Importance of vital signs to the early diagnosis and severity of sepsis: 
association between vital signs and sequential organ failure assessment score in 
patients with sepsis. Internal medicine (Tokyo, Japan). 2012;51(8):871-6. 
108. Levy MM, Macias WL, Vincent JL, Russell JA, Silva E, Trzaskoma B, et al. 
Early changes in organ function predict eventual survival in severe sepsis. Crit 
Care Med. 2005;33(10):2194-201. 
109. Russell JA, Singer J, Bernard GR, Wheeler A, Fulkerson W, Hudson L, et al. 
Changing pattern of organ dysfunction in early human sepsis is related to 
mortality. Crit Care Med. 2000;28(10):3405-11. 
110. Cretikos MA, Bellomo R, Hillman K, Chen J, Finfer S, Flabouris A. 
Respiratory rate: the neglected vital sign. The Medical journal of Australia. 
2008;188(11):657-9. 
   63 
111. Martin GS, Bernard GR. Airway and lung in sepsis. Intensive Care Med. 
2001;27 Suppl 1:S63-79. 
112. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et 
al. Defining community acquired pneumonia severity on presentation to 
hospital: an international derivation and validation study. Thorax. 
2003;58(5):377-82. 
113. Wallgren UM, Castren M, Svensson AE, Kurland L. Identification of adult 
septic patients in the prehospital setting: a comparison of two screening tools 
and clinical judgment. European journal of emergency medicine : official 
journal of the European Society for Emergency Medicine. 2013. 
114. Jaderling GMD, Bell MMDP, Martling C-RMDP, Ekbom AMDP, Bottai MS, 
Konrad DMDP. ICU Admittance by a Rapid Response Team Versus 
Conventional Admittance, Characteristics, and Outcome*. Critical Care 
Medicine. 2013;41(3):725-31. 
115. Weiss G, Goodnough LT. Anemia of Chronic Disease. New England Journal of 
Medicine. 2005;352(10):1011-23. 
116. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin 
and C-reactive protein levels as markers of bacterial infection: a systematic 
review and meta-analysis. Clin Infect Dis. 2004;39(2):206-17. 
117. Chan YL, Tseng CP, Tsay PK, Chang SS, Chiu TF, Chen JC. Procalcitonin as a 
marker of bacterial infection in the emergency department: an observational 
study. Crit Care. 2004;8(1):R12-20. 
118. Gaini S, Koldkjaer OG, Pedersen C, Pedersen SS. Procalcitonin, 
lipopolysaccharide-binding protein, interleukin-6 and C-reactive protein in 
community-acquired infections and sepsis: a prospective study. Crit Care. 
2006;10(2):R53. 
119. Gonçalves-Pereira J, Povoa PR, Lobo C, Carneiro AH. Bloodstream infections 
as a marker of community-acquired sepsis severity. Results from the Portuguese 
community-acquired sepsis study (SACiUCI study). Clinical Microbiology and 
Infection. 2013;19(3):242-8. 
120. Jones GR, Lowes JA. The systemic inflammatory response syndrome as a 
predictor of bacteraemia and outcome from sepsis. QJM. 1996;89(7):515-22. 
121. Laupland KB, Gregson DB, Zygun DA, Doig CJ, Mortis G, Church DL. Severe 
bloodstream infections: a population-based assessment. Crit Care Med. 
2004;32(4):992-7. 
122. Chirouze C, Schuhmacher H, Rabaud C, Gil H, Khayat N, Estavoyer JM, et al. 
Low serum procalcitonin level accurately predicts the absence of bacteremia in 
adult patients with acute fever. Clin Infect Dis. 2002;35(2):156-61. 
123. Muller F, Christ-Crain M, Bregenzer T, Krause M, Zimmerli W, Mueller B, et 
al. Procalcitonin levels predict bacteremia in patients with community-acquired 
pneumonia: a prospective cohort trial. Chest. 2010;138(1):121-9. 
124. Tromp M, Lansdorp B, Bleeker-Rovers CP, Gunnewiek JM, Kullberg BJ, 
Pickkers P. Serial and panel analyses of biomarkers do not improve the 
prediction of bacteremia compared to one procalcitonin measurement. J Infect. 
2012;65(4):292-301. 
125. Heyland DKMDFM, Johnson APP, Reynolds SCMDF, Muscedere JMDF. 
Procalcitonin for reduced antibiotic exposure in the critical care setting: A 
systematic review and an economic evaluation *. Critical Care Medicine. 
2011;39(7):1792-9. 
126. Schuetz P, Chiappa V, Briel M, Greenwald JL. Procalcitonin algorithms for 
antibiotic therapy decisions: a systematic review of randomized controlled trials 
 64 
and recommendations for clinical algorithms. Arch Intern Med. 
2011;171(15):1322-31. 
127. Jensen JU, Heslet L, Jensen TH, Espersen K, Steffensen P, Tvede M. 
Procalcitonin increase in early identification of critically ill patients at high risk 
of mortality. Crit Care Med. 2006;34(10):2596-602. 
128. Schuetz P, Maurer P, Punjabi V, Desai A, Amin DN, Gluck E. Procalcitonin 
decrease over 72 hours in US critical care units predicts fatal outcome in sepsis 
patients. Crit Care. 2013;17(3):R115. 
129. Bouchon A, Facchetti F, Weigand MA, Colonna M. TREM-1 amplifies 
inflammation and is a crucial mediator of septic shock. Nature. 
2001;410(6832):1103-7. 
130. Gibot S, Kolopp-Sarda MN, Bene MC, Cravoisy A, Levy B, Faure GC, et al. 
Plasma level of a triggering receptor expressed on myeloid cells-1: its 
diagnostic accuracy in patients with suspected sepsis. Ann Intern Med. 
2004;141(1):9-15. 
131. Gibot S. Clinical review: role of triggering receptor expressed on myeloid cells-
1 during sepsis. Crit Care. 2005;9(5):485-9. 
132. Jeong SJ, Song YG, Kim CO, Kim HW, Ku NS, Han SH, et al. Measurement of 
plasma sTREM-1 in patients with severe sepsis receiving early goal-directed 
therapy and evaluation of its usefulness. Shock. 2012;37(6):574-8. 
133. Latour-Perez J, Alcala-Lopez A, Garcia-Garcia MA, Sanchez-Hernandez JF, 
Abad-Terrado C, Viedma-Contreras JA, et al. Diagnostic accuracy of sTREM-1 
to identify infection in critically ill patients with systemic inflammatory 
response syndrome. Clinical biochemistry. 2010;43(9):720-4. 
134. Kofoed K, Andersen O, Kronborg G, Tvede M, Petersen J, Eugen-Olsen J, et al. 
Use of plasma C-reactive protein, procalcitonin, neutrophils, macrophage 
migration inhibitory factor, soluble urokinase-type plasminogen activator 
receptor, and soluble triggering receptor expressed on myeloid cells-1 in 
combination to diagnose infections: a prospective study. Crit Care. 
2007;11(2):R38. 
135. Jiyong J, Tiancha H, Wei C, Huahao S. Diagnostic value of the soluble 
triggering receptor expressed on myeloid cells-1 in bacterial infection: a meta-
analysis. Intensive Care Med. 2009;35(4):587-95. 
136. Linder A, Akesson P, Inghammar M, Treutiger CJ, Linner A, Sunden-Cullberg 
J. Elevated plasma levels of heparin-binding protein in intensive care unit 
patients with severe sepsis and septic shock. Crit Care. 2012;16(3):R90. 
137. Llewelyn M, Berger M, Gregory M, Ramaiah R, Taylor A, Curdt I, et al. Sepsis 
biomarkers in unselected patients on admission to intensive or high-dependency 
care. Critical Care. 2013;17(2):R60. 
138. Chew MS, Linder A, Santen S, Ersson A, Herwald H, Thorlacius H. Increased 
plasma levels of heparin-binding protein in patients with shock: a prospective, 
cohort study. Inflammation research : official journal of the European 
Histamine Research Society  [et al]. 2012;61(4):375-9. 
139. Gibot S, Bene MC, Noel R, Massin F, Guy J, Cravoisy A, et al. Combination 
Biomarkers to Diagnose Sepsis in the Critically Ill Patient. Am J Respir Crit 
Care Med. 2012. 
140. Shapiro NI, Trzeciak S, Hollander JE, Birkhahn R, Otero R, Osborn TM, et al. 
A prospective, multicenter derivation of a biomarker panel to assess risk of 
organ dysfunction, shock, and death in emergency department patients with 
suspected sepsis. Crit Care Med. 2009;37(1):96-104. 
141. Ljungstrom LR, Steinum O, Brink M, Gardlund B, Martner J, Sjolin J. 
[Diagnosis and diagnostic coding of severe sepsis and septic shock. ICD-10 
   65 
should be completed with additional codes]. Lakartidningen. 2011;108(6):276-
8. 
142. Sprung CL, Sakr Y, Vincent JL, Le Gall JR, Reinhart K, Ranieri VM, et al. An 
evaluation of systemic inflammatory response syndrome signs in the Sepsis 
Occurrence In Acutely Ill Patients (SOAP) study. Intensive Care Med. 
2006;32(3):421-7. 
143. Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, et al. 
Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of 
death. N Engl J Med. 2005;353(13):1332-41. 
144. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-
Rodriguez A, et al. Efficacy and safety of recombinant human activated protein 
C for severe sepsis. N Engl J Med. 2001;344(10):699-709. 
145. Alberti C, Brun-Buisson C, Goodman SV, Guidici D, Granton J, Moreno R, et 
al. Influence of systemic inflammatory response syndrome and sepsis on 
outcome of critically ill infected patients. Am J Respir Crit Care Med. 
2003;168(1):77-84. 
146. Bossink AW, Groeneveld J, Hack CE, Thijs LG. Prediction of mortality in 
febrile medical patients: How useful are systemic inflammatory response 
syndrome and sepsis criteria? Chest. 1998;113(6):1533-41. 
147. Dremsizov T, Clermont G, Kellum JA, Kalassian KG, Fine MJ, Angus DC. 
Severe sepsis in community-acquired pneumonia: when does it happen, and do 
systemic inflammatory response syndrome criteria help predict course? Chest. 
2006;129(4):968-78. 
148. Salvo I, de Cian W, Musicco M, Langer M, Piadena R, Wolfler A, et al. The 
Italian SEPSIS study: preliminary results on the incidence and evolution of 
SIRS, sepsis, severe sepsis and septic shock. Intensive Care Med. 1995;21 
Suppl 2:S244-9. 
149. Gaieski DF, Mikkelsen ME, Band RA, Pines JM, Massone R, Furia FF, et al. 
Impact of time to antibiotics on survival in patients with severe sepsis or septic 
shock in whom early goal-directed therapy was initiated in the emergency 
department. Crit Care Med. 2010;38(4):1045-53. 
150. Puskarich MAMD, Trzeciak SMD, Shapiro NIMD, Arnold RCMD, Horton 
JMMD, Studnek JRP, et al. Association between timing of antibiotic 
administration and mortality from septic shock in patients treated with a 
quantitative resuscitation protocol *. Critical Care Medicine. 2011;39(9):2066-
71. 
151. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, et al. 
The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ 
dysfunction/failure. On behalf of the Working Group on Sepsis-Related 
Problems of the European Society of Intensive Care Medicine. Intensive Care 
Med. 1996;22(7):707-10. 
152. Jones AE, Trzeciak S, Kline JA. The Sequential Organ Failure Assessment 
score for predicting outcome in patients with severe sepsis and evidence of 
hypoperfusion at the time of emergency department presentation. Crit Care 
Med. 2009;37(5):1649-54. 
153. Howell MD, Donnino M, Clardy P, Talmor D, Shapiro NI. Occult 
hypoperfusion and mortality in patients with suspected infection. Intensive Care 
Med. 2007;33(11):1892-9. 
154. Nguyen HB, Rivers EP, Knoblich BP, Jacobsen G, Muzzin A, Ressler JA, et al. 
Early lactate clearance is associated with improved outcome in severe sepsis 
and septic shock. Crit Care Med. 2004;32(8):1637-42. 
 66 
155. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. 
Surviving sepsis campaign: international guidelines for management of severe 
sepsis and septic shock: 2012. Crit Care Med. 2013;41(2):580-637. 
156. Klein Klouwenberg PM, Ong DS, Bonten MJ, Cremer OL. Classification of 
sepsis, severe sepsis and septic shock: the impact of minor variations in data 
capture and definition of SIRS criteria. Intensive Care Med. 2012;38(5):811-9. 
157. Marshall JC, Foster D, Vincent JL, Cook DJ, Cohen J, Dellinger RP, et al. 
Diagnostic and prognostic implications of endotoxemia in critical illness: 
results of the MEDIC study. The Journal of infectious diseases. 
2004;190(3):527-34. 
158. Lowry SF. Human endotoxemia: a model for mechanistic insight and 
therapeutic targeting. Shock. 2005;24 Suppl 1:94-100. 
159. Kamei M, Carman CV. New observations on the trafficking and diapedesis of 
monocytes. Curr Opin Hematol. 2010;17(1):43-52. 
160. Kondo T, Kawai T, Akira S. Dissecting negative regulation of Toll-like 
receptor signaling. Trends Immunol. 2012;33(9):449-58. 
161. Ertel W, Kremer J, Kenney J, Steckholzer U, Jarrar D, Trentz O, et al. 
Downregulation of proinflammatory cytokine release in whole blood from 
septic patients. Blood. 1995;85(5):1341-7. 
162. Blanco J, Muriel-Bombin A, Sagredo V, Taboada F, Gandia F, Tamayo L, et al. 
Incidence, organ dysfunction and mortality in severe sepsis: a Spanish 
multicentre study. Crit Care. 2008;12(6):R158. 
163. Monneret G, Finck ME, Venet F, Debard AL, Bohe J, Bienvenu J, et al. The 
anti-inflammatory response dominates after septic shock: association of low 
monocyte HLA-DR expression and high interleukin-10 concentration. Immunol 
Lett. 2004;95(2):193-8. 
164. Tamayo E, Fernandez A, Almansa R, Carrasco E, Heredia M, Lajo C, et al. 
Pro- and anti-inflammatory responses are regulated simultaneously from the 
first moments of septic shock. Eur Cytokine Netw. 2011;22(2):82-7. 
165. Park SH, Park-Min KH, Chen J, Hu X, Ivashkiv LB. Tumor necrosis factor 
induces GSK3 kinase-mediated cross-tolerance to endotoxin in macrophages. 
Nat Immunol. 2011. 
166. Hoogerwerf JJ, de Vos AF, van't Veer C, Bresser P, de Boer A, Tanck MWT, et 
al. Priming of Alveolar Macrophages upon Instillation of Lipopolysaccharide in 
the Human Lung. Am J Respir Cell Mol Biol. 2010;42(3):349-56. 
167. Cavaillon JM, Annane D. Compartmentalization of the inflammatory response 
in sepsis and SIRS. J Endotoxin Res. 2006;12(3):151-70. 
168. Venet F, Lukaszewicz AC, Payen D, Hotchkiss R, Monneret G. Monitoring the 
immune response in sepsis: a rational approach to administration of 
immunoadjuvant therapies. Curr Opin Immunol. 2013;25(4):477-83. 
169. Monneret G, Lepape A, Voirin N, Bohé J, Venet F, Debard A-L, et al. 
Persisting low monocyte human leukocyte antigen-DR expression predicts 
mortality in septic shock. Intensive Care Medicine. 2006;32(8):1175-83. 
170. Landelle C, Lepape A, Voirin N, Tognet E, Venet F, Bohé J, et al. Low 
monocyte human leukocyte antigen-DR is independently associated with 
nosocomial infections after septic shock. Intensive Care Medicine. 
2010;36(11):1859-66. 
171. Boomer JS, To K, Chang KC, Takasu O, Osborne DF, Walton AH, et al. 
Immunosuppression in patients who die of sepsis and multiple organ failure. 
JAMA. 2011;306(23):2594-605. 
172. Payen D, Monneret G, Hotchkiss R. Immunotherapy - a potential new way 
forward in the treatment of sepsis. Crit Care. 2013;17(1):118. 
   67 
173. Monneret G, Venet F, Pachot A, Lepape A. Monitoring immune dysfunctions 
in the septic patient: a new skin for the old ceremony. Mol Med. 2008;14(1-
2):64-78. 
174. Dinarello CA. Interleukin-1 and interleukin-1 antagonism. Blood. 
1991;77(8):1627-52. 
175. Kobayashi Y. The role of chemokines in neutrophil biology. Frontiers in 
bioscience : a journal and virtual library. 2008;13:2400-7. 
176. Mantovani A, Cassatella MA, Costantini C, Jaillon S. Neutrophils in the 
activation and regulation of innate and adaptive immunity. Nat Rev Immunol. 
2011;11(8):519-31. 
177. Cassatella MA. Neutrophil-derived proteins: selling cytokines by the pound. 
Advances in immunology. 1999;73:369-509. 
178. Altstaedt J, Kirchner H, Rink L. Cytokine production of neutrophils is limited 
to interleukin-8. Immunology. 1996;89(4):563-8. 
 
 
